Stockwinners Market Radar for June 09, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment bought 75.1K shares of Roblox today

19:45 EDT Poshmark director sells $1.0M in common stock - In a regulatory filing, Poshmark disclosed that its director Hans Tung sold 85.8K shares of common stock on June 7th in a total transaction size of $1.0M.

19:27 EDT AMD announces Technology and Product Portfolio updates - AMD "announced expanded multi-generational CPU core, graphics, and adaptive computing architecture roadmaps including new details on the: "Zen 4" CPU core expected to power the world's first high-performance 5nm x86 CPUs later this year. "Zen 4" is expected to increase IPC 8%-10%1 and deliver more than a 25% increase in performance-per-watt2 and 35% overall performance increase compared to "Zen 3" when running desktop applications. "Zen 5" CPU core planned for 2024, which is built from the ground up to deliver performance and efficiency leadership across a broad range of workloads and features and includes optimizations for AI and machine learning. AMD RDNA(TM) 3 gaming architecture that combines a chiplet design, next generation AMD Infinity Cache(TM) technology, leading-edge 5nm manufacturing technology, and other enhancements to deliver more than 50% greater performance-per-watt compared to the prior generation. 4th Gen Infinity Architecture that further extends AMD's leadership modular SoC design approach with a high-speed interconnect, allowing seamless integration of both AMD IP and 3rd party chiplets to enable an entirely new class of high-performance and adaptive processors and providing a custom-ready heterogenous computing platform. AMD CDNA(TM) 3 architecture, which combines 5nm chiplets, 3D die stacking, 4th generation Infinity Architecture, next-generation AMD Infinity Cache(TM) technology, and HBM memory in a single package with a unified memory programming model. The first AMD CDNA 3 architecture-based products are planned for 2023 and are expected to deliver more than 5X greater performance-per-watt compared to AMD CDNA 2 architecture on AI training workloads. AMD XDNA, the foundational architecture IP from Xilinx that consists of key technologies including the FPGA fabric and AI Engine. The FPGA fabric combines an adaptive interconnect with FPGA logic and local memory, while the AIE provides a dataflow architecture optimized for high performance and energy efficient AI and signal processing applications. AMD plans to integrate AMD XDNA IP across multiple products in the future, starting with AMD Ryzen processors planned for 2023."

19:09 EDT Indus Realty Trust acquires 205K sqf portfolio in Florida for $31.6M - INDUS Realty Trust "announced that it has closed on the purchase of a fully leased, approximately 205,000 square foot portfolio located in the Orlando and Palm Beach, Florida markets. The Company used cash on hand to pay the $31.6 million purchase price before transaction costs, which equates to an in-place cash capitalization rate of approximately 4.6%."

18:15 EDT FDA panel unanimously endorses Bluebird's eli-cel gene therapy - Bluebird Bio announced the outcome of the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee discussion of elivaldogene autotemcel, or eli-cel, for the treatment of early active cerebral adrenoleukodystrophy in patients less than 18 years of age who do not have an available and willing human leukocyte antigen-matched sibling hematopoietic stem cell donor. On the question "Do the benefits of eli-cel outweigh the risks, for the treatment of any sub-population of children with early active cerebral adrenoleukodystrophy (CALD)?" the CTGTAC voted 15 (yes) to 0 (no). "For decades, the CALD community has fought for the opportunity to stave off the rapid, irreversible decline associated with this devastating disease," said Andrew Obenshain, chief executive officer, bluebird bio. "Today we are one step closer to delivering a potentially lifesaving therapy for CALD. We are grateful to the families, clinicians and committee members who participated in today's advisory committee discussion and remain committed to working with the FDA as it completes its review of the eli-cel Biologics License Application."

18:05 EDT Altamira Therapeutics discloses Nasdaq notice on minimum listing requirements - Altamira Therapeutics "announced that on June 02, 2022 the Company received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that the minimum bid price per share for its common shares was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)."

17:24 EDT NY Court approves $300M settlement in Renren derivative litigation - The New York State Supreme Court granted approval of a direct pay cash settlement totaling at least $300M resolving the In re Renren, Inc. Derivative Litigation, one of the largest cash settlements of a derivative action in history. The action alleges a complex scheme by Renren insiders to take the company's billion-dollar investment portfolio for themselves. Reid Collins & Tsai LLP, Lead Counsel for the derivative plaintiffs, originally announced the terms of the settlement in October 2021. Reid Collins Founding Partner William Reid, IV on the resolution of the Renren litigation: "This is an extraordinary result by any measure. It is very rare to settle a case for more than the damages that we originally pleaded. Yet indeed, from the vantage point of minority shareholders, we have recovered more for them in this direct pay settlement than the damage claim we set forth in the complaint. Obtaining jurisdiction over these foreign defendants was no small task, but obtaining derivative standing was an even greater achievement. What little New York law existed on establishing derivative standing under Cayman law was adverse, but the facts of this case and a thorough presentation of Cayman law nonetheless allowed us to establish that the minority were in fact entitled to pursue the company's claim under the 'fraud on the minority' exception to the general rule against derivative standing. I could not be more proud of what we have accomplished in Renren, and of our clients, including Heng Ren Silk Investments, LLC in taking on this significant and important challenge."

17:19 EDT Stitch Fix sees restructuring, one-time charges of $15M-$20M in Q4 from layoffs - Sees elevated product and transformation costs in Q4. Says job cuts span all types of positions and levels. Sees net active clients in Q4 down quarter-over-quarter.

17:14 EDT Wells Fargo pauses diverse slate guidelines, conducts review of hiring - Wells Fargo & Company issued the following statement responding to a New York Times article published Thursday: "No one should be put through an interview without a real chance of receiving an offer, period. The diverse slate guidelines we put in place are meant to increase diverse representation across the company and we can see meaningful results in our hiring data since 2020. At the same time, it's important that implementation of our guidelines is consistent. Earlier this week, the company temporarily paused the use of its diverse slate guidelines. During this pause, the company is conducting a review so that hiring managers, senior leaders and recruiters fully understand how the guidelines should be implemented - and so we can have confidence that our guidelines live up to their promise."

17:12 EDT Cactus CEO sells $30.4K shares of common stock - In a regulatory filing, Cactus disclosed that its CEO Scott Bender sold 562K shares of common stock on June 7th in a total transaction of $30.4M.

17:02 EDT Oceaneering to partner w/ Collins Aerospace, ILC Dover on NASA spacesuit program - Oceaneering "announces that Oceaneering Space Systems, a division of the Aerospace and Defense Technologies segment, will serve on a team led by Collins Aerospace, a Raytheon Technologies business selected by the National Aeronautics and Space Administration to develop next-generation extravehicular spacesuits. NASA is enlisting commercial partners to develop, build, and maintain new spacesuit technology. The Collins team, which also includes ILC Dover, has decades of experience supplying spacesuits to NASA. Collins is one of two companies that received access to a NASA contract for Extravehicular Activity Services worth up to $3.5B over 12 years to supply spacesuits for future missions."

16:58 EDT Angi Inc. reports May revenue up 24% y/y

16:52 EDT Wesco Chief Transformation Officer Theodore Dosch to retire - Wesco International announces the retirement of Theodore Dosch, executive VP, Strategy and Chief Transformation Officer, effective August 5. Dosch has served in this position since June 2020 upon the completion of Wesco's transaction with Anixter. He previously served as Anixter's executive VP - Finance and CFO.

16:46 EDT Illumina drops 6% to $210.00 after departure of CFO

16:40 EDT Vail Resorts jumps 6% to $261.00 after Q3 results beat estimates

16:32 EDT VICI Properties enters into new pacts relating to Gold Strike Casino Resort - VICI Properties Inc. (VICI) announced that, in connection with MGM Resorts International's (MGM) agreement to sell the operations of Gold Strike Casino Resort, located in Tunica, MS, to Cherokee Nation Entertainment Gaming Holdings, LLC, a subsidiary of Cherokee Nation Businesses, VICI has agreed to enter into a new separate lease with CNB related to the operations of Gold Strike and also enter into an amendment to the Master Lease between VICI Properties and MGM Resorts. John Payne, President and Chief Operating Officer of VICI Properties, said, "This transaction continues to demonstrate VICI's ability to build strong relationships with new partners while working collaboratively with existing tenants to support their strategic objectives. We are pleased to welcome Cherokee Nation Businesses as our ninth gaming tenant and we look forward to a long-term partnership as they pursue additional growth initiatives in the future." VICI Properties has also agreed, in accordance with, and as contemplated by, the terms of the MGM Master Lease, to amend the MGM Master Lease to account for MGM's divestiture of the operations of Gold Strike, which will result in a reduction of the initial annual base rent under the MGM Master Lease by $40M. The transactions referenced herein are expected to be completed in the first half of 2023 and are subject to customary closing conditions and regulatory approvals.

16:23 EDT Quest Diagnostics appoints Sam Samad as CFO - Quest Diagnostics has appointed Sam Samad as Executive VP and CFO. He will succeed Mark Guinan, who, in February, following eight and a half years in the role, announced his intention to retire. To provide a smooth transition, Mr. Guinan will remain at Quest through the report of Q2 financial results. Samad will join Quest Diagnostics on July 11. Samad joins Quest from Illumina, where he has served as CFO since 2017. Before joining Illumina, Samad held several senior leadership positions at Cardinal Health, including SVP and Corporate Treasurer. Prior to Cardinal Health, he spent 13 years at Eli Lilly in a variety of sales and finance roles, both domestically and internationally, including as CFO of the company's Canada affiliate.

16:21 EDT AllianceBernstein reports preliminary AUM $687B as of May 31 - Up from $685B at the end of April. The increase was due to firm-wide net inflows and slight market appreciation. By channel, net inflows to Institutions were partially offset by modest net outflows from Retail and Private Wealth.

16:16 EDT FleetCor to acquire UK-based cross-border business - FLEETCOR "announced it has signed a definitive agreement to acquire the Global Reach Group, a UK-based cross-border payments provider. With the acquisition, FLEETCOR(R) increases its cross-border payments scale and strengthens its position as one of the largest non-bank global cross-border providers in the world. The transaction is expected to close in the fourth quarter of 2022, subject to regulatory approval and standard closing conditions."

16:15 EDT DocuSign reports Q1 subscription revenue $569.3M, up 26% y/y - Professional services and other revenue was $19.4M, an increase of 13% year-over-year. Billings were $613.6M, an increase of 16% year-over-year. GAAP gross margin was 78% for both periods. Non-GAAP gross margin was 81% for both periods.

16:13 EDT IAC reports May Angi Inc. total revenue up 24% from last year - As part of its May monthly metrics disclosure, IAC also reports Dotdash Meredith total pro-forma revenue down 10%, and its Search business revenue up 30% from last year. Emerging & Other revenue was up 4% from last year.

16:10 EDT DocuSign drops 12% to $76.88 after Q1 profit misses estimates

16:06 EDT National Storage names David Cramer president and COO - National Storage Affiliates Trust announced the promotion, effective July 1, 2022, of David Cramer from his role as Executive Vice President and Chief Operating Officer to President and Chief Operating Officer. Tamara Fischer, Chief Executive Officer, commented, "We are extremely pleased to announce Dave's promotion to President of NSA. This promotion acknowledges his current and growing responsibilities and ongoing contributions to our Company's success. We believe the Company will benefit from Dave's elevated leadership role as well as his focus on operational execution and growth through acquisitions given his invaluable industry experience and proven track record of results."

16:06 EDT FCPT announces $32.5M outparcel portfolio with PREIT - Four Corners Property Trust (FCPT) announced that it has signed a definitive agreement for the purchase of 11 outparcel properties from PREIT (PEI) for $32.5M. The transaction is priced at a 6.5% going-in cash cap rate, exclusive of transaction costs. The portfolio includes 8 single tenant restaurant properties and three non-restaurant retail properties. FCPT expects to acquire a majority of the portfolio in the second and third quarters of 2022, subject to customary closing conditions, seller's board approval, and regulatory approvals. Bill Lenehan, CEO of Four Corners Property Trust, stated: "We have previously executed multiple outparcel transactions with the PREIT team and they have been an exceptional partner for us. We are excited to announce this 11-property outparcel portfolio and to continue our strategy of identifying low-rent outparcel properties leased to strong credit operators."

16:02 EDT Paltalk acquires Visicom's ManyCam assets - Paltalk announced that it has acquired the core assets of ManyCam from Visicom Media. ManyCam is a live streaming software and virtual camera that allows users to deliver professional live videos on any streaming platform, video conferencing app or distance learning tool. The purchase price for the ManyCam assets was $2.7M in cash consideration, plus a potential earn-out payment of up to $600,000 upon the achievement of certain performance thresholds related to gross sales of ManyCam software over the six-month period following the closing of the acquisition.

15:33 EDT AeroClean Technologies Inc trading resumes

15:15 EDT Take-Two's 'Marvel's Midnight Suns' out October 7, 2022 - Take-Two's (TTWO) 2K and Disney's (DIS) Marvel announced strategy video game "Marvel's Midnight Suns" will launch on October 7, 2022. Created by Firaxis Games, the legendary studio behind the "Civilization" and "XCOM" franchises, "Marvel's Midnight Suns" is an all-new tactical RPG set in the darker side of the Marvel Universe. It will be available on PlayStation 5 (SONY), PlayStation 4, Xbox Series X S (MSFT) , Xbox One, and Windows PC via Steam and Epic Games Store. The Nintendo Switch (NTDOY) version of the game will be available at a later date. Rated T for Teen by the ESRB, Marvel's Midnight Suns is now available for pre-order.

14:03 EDT Amazon introduces Virtual Try-On for Shoes - Amazon said in a blog post that it is introducing Virtual Try-On for Shoes, an interactive mobile experience that allows customers to visualize how a pair of shoes will look on themselves from every angle and to better inform purchasing decisions, from the comfort of their home or on the go. Available for customers in the U.S. and Canada, Virtual Try-On for Shoes can be accessed via the Amazon shopping app on iOS. Thousands of sneaker styles are currently available from brands including New Balance, adidas, Reebok, Puma, Superga, Lacoste, Asics, and Saucony. Reference Link

13:45 EDT TAT Technologies trading halted, volatility trading pause

13:02 EDT NHTSA expands probe of Tesla full self-driving system - The National Highway Traffic Safety Administration, or NHTSA, has expanded an investigation into Tesla's FSD, or "full self-driving," autopilot system after about a dozen collisions at crash scenes. The probe, initially announced by the National Highway Traffic Safety Administration in August, was widened to cover an estimated 830,000 Tesla Model Y, X, S and 3 vehicles from a previous estimated total of 765,000 vehicles, documents posted to the website of the NHTSA show. The NHTSA said the vehicles now under investigation have been involved in 14 crashes that resulted in one fatality. The probe was also converted from a preliminary investigation to an engineering analysis, according to the documents.

12:33 EDT Porsche acquires eBike system manufacturer Fazua, terms not disclosed - Porsche (POAHY), a subsidiary of Volkswagen (VWAGY), has acquired Fazua, a manufacturer of particularly light and compact drive systems for eBikes. "In Fazua, we have found a strong partner with a great deal of experience in the bicycle industry," says Lutz Meschke, Deputy Chairman of the Executive Board of Porsche AG and Member of the Executive Board for Finance and IT. "Fazua is known among experts as the founder of the 'light eBikes' category - and it's a highly innovative company that fits perfectly with the pioneering spirit of the Porsche brand." After buying into the company with a 20% stake in January, Porsche now acquires all of Fazua's shares.

12:00 EDT Gelesis falls -18.0% - Gelesis is down -18.0%, or -68c to $3.10.

12:00 EDT Forge Global falls -29.5% - Forge Global is down -29.5%, or -$4.24 to $10.15.

12:00 EDT Signet Jewelers rises 9.3% - Signet Jewelers is up 9.3%, or $5.80 to $68.00.

11:36 EDT SpartanNash says shareholders elect all company director nominees - SpartanNash announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2022 Annual Meeting of Shareholders, SpartanNash shareholders have voted, with a substantial margin, to re-elect all nine of its highly qualified, independent director nominees - Douglas Hacker, Shan Atkins, Matthew Mannelly, Julien Mininberg, Jaymin Patel, Maj. Gen. Hawthorne Proctor, Pamela Puryear, Ph.D., Tony Sarsam, and William Voss - to the Company's Board of Directors. SpartanNash issued the following statement: "We appreciate the significant support for the Company's plan that we have received from our shareholders throughout this process. Today's outcome reinforces that SpartanNash shareholders recognize that the Company's strategy is working, and the Company has the right Board in place to continue guiding the business forward. The Board and management team will remain focused on executing the Company's ongoing transformation through our operating model and People First culture to drive long-term, sustainable value creation for our shareholders. We thank our 17,500 SpartanNash Associates for their continued dedication to serving our customers, our store guests and one another." The preliminary voting also indicated that shareholders approved all of the other proposals submitted for a vote at the Annual Meeting.

11:31 EDT Gap launches new credit card program in partnership with Barclays, MasterCard - Gap Inc. (GPS) announced the launch of a new suite of credit cards with Barclays US Consumer Bank (BCS). "First announced last year, Barclays is now the official issuer of Gap Inc.'s co-branded and private label credit card program in the U.S. and Puerto Rico through the Mastercard global payment network. Gap Inc.'s existing 10 million Cardmembers will be fully migrated to the Barclays program and will receive their cards later this month. Customers who are interested in becoming a Cardmember can apply online or through any of the company's retail stores in the U.S. and Puerto Rico," Gap stated.

11:30 EDT Microsoft, Samsung partner to bring Xbox Cloud Gaming to Samsung Smart TVs - Microsoft (MSFT) said it is partnering with Samsung (SSNLF) to bring its Xbox Cloud Gaming to Samsung's 2022 Smart TVs. The move follows a similar partnership that brought Xbox Game Pass to Samsung Galaxy phones. "I'm excited for you to experience cloud gaming on Smart TVs on June 30 in 27 countries," Microsoft said. "Playing Xbox games on 2022 Samsung Smart TVs gives Xbox Game Pass Ultimate members easy and instant access to over 100 high-quality games, including Xbox Game Studios titles on the same day they release. And as we recently announced, you can also play Fortnite without a membership through cloud gaming. The Xbox app on Smart TVs presents new opportunities to play: If you are getting a new Samsung 2022 Smart TV, you will now have more ways to play games in your house. If you're new to gaming, this is an easy way to get into the fun without needing to buy a PC or console and also to join a thriving community of over 25 million Game Pass members worldwide. We are bringing the Xbox App to Samsung Smart TVs first, and our intent is to explore other TV partnerships as part of this next evolution in our vision." Reference Link

11:18 EDT Alleghany stockholders approve acquisition by Berkshire Hathaway - Alleghany Corporation announced that its stockholders voted to approve and adopt the Agreement and Plan of Merger, dated as of March 20, 2022, pursuant to which Alleghany will be acquired by Berkshire Hathaway for $848.02 per share of common stock in cash. During the special meeting of stockholders held today, approximately 84% of Alleghany's outstanding common shares, and more than 98% of the votes cast, voted in favor of the merger proposal. The final voting results at the special meeting will be set forth in a Current Report on Form 8-K to be filed by Alleghany with the U.S. Securities and Exchange Commission. In addition to the approval today by Alleghany stockholders, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired in early May. The transaction is expected to close in the fourth quarter of 2022, subject to customary closing conditions and regulatory approvals.

11:07 EDT PNC Financial, AEG Presents sign agreement to rename plazas at Fiddler's Green - PNC Bank has signed an agreement with AEG Presents to rename two central plazas at Fiddler's Green Amphitheatre. Effective immediately, the financial institution will become the exclusive banking partner of the iconic amphitheater - operated by AEG Presents and Museum of Outdoor Arts and the venue's two main plazas will be known as "PNC Plaza North" and "PNC Plaza South." As part of the agreement, PNC's branding will be featured prominently across the venue's social and digital channels as well as on-site at both "PNC Plaza North" and "PNC Plaza South." Located at the north and south ends of the venue, the plazas will serve as key gathering areas for fans to enjoy throughout the year. Integral to the overall design of Fiddler's Green itself, the plazas will also be used to enhance the guest experience with special on-site activations including pre-event parties, community events, fan fests and more.

10:48 EDT Caesars Entertainment forms partnership with Peyton Manning's Omaha Productions - Caesars Entertainment announced a multiyear strategic partnership with Peyton Manning's Omaha Productions. Together, Caesars Sportsbook and Omaha Productions will launch the Omaha Audio Network, a full-service audio production network, a variety of new digital series developed specifically for Caesars Entertainment and Omaha Productions' social media channels, and a live event series later this year.

10:04 EDT ISG expands Enate partnership to include the U.S. - ISG Automation said it has extended its existing partnership with Enate to provide Enate's process orchestration platform solution to clients in the United States. Under the extended partnership, ISG Automation will offer its U.S. clients the Enate open platform, which is able to plug and play with any automation technology-including RPA, AI, cognitive, NLP and machine learning-from any vendor. ISG will also support the efforts of Enate, a U.K.-based global company, to expand its presence in the U.S. market.

10:02 EDT Pfizer announces completion of acquisition of ReViral - Pfizer announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus. Under the terms of the agreement, Pfizer acquired ReViral for a total consideration of up to $525M, including upfront and development milestones. If successful, Pfizer believes annual revenue for these programs has the potential to reach or exceed $1.5B. "We are excited to bring ReViral's promising investigational treatments for RSV into our anti-infective pipeline at Pfizer. This acquisition further demonstrates our commitment to advancing pioneering science - both through our in-house expertise and our work with leading, innovative companies - with the goal of delivering new breakthroughs to patients suffering from serious infectious diseases. We believe these therapeutic candidates - and the scientific expertise that has advanced their development - will complement our ongoing work to help combat RSV infections, and we look forward to welcoming our new colleagues to further support these endeavors," said Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer.

10:00 EDT Skillsoft falls -16.9% - Skillsoft is down -16.9%, or -$1.07 to $5.27.

10:00 EDT Li-Cycle rises 9.9% - Li-Cycle is up 9.9%, or 70c to $7.80.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas rises 13.3% - ProShares UltraShort Bloomberg Natural Gas is up 13.3%, or $2.71 to $23.10.

09:51 EDT Knightscope signs new contract in Houston, Texas - Knightscope announced that it has a new contract in Houston, Texas. This New York based investor, developer, owner and operator has more than 16,500 apartments in 18 states with a national footprint that includes more than $6B in assets and identified pipeline, Knightscope said in a statement. The K5 Autonomous Security Robot will be helping to deter crime and loitering in an effort to create a safer and more secure community, it said.

09:47 EDT Skillsoft falls -13.0% - Skillsoft is down -13.0%, or -82c to $5.51.

09:47 EDT Zegna rises 9.7% - Zegna is up 9.7%, or 93c to $10.55.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas rises 13.6% - ProShares UltraShort Bloomberg Natural Gas is up 13.6%, or $2.77 to $23.16.

09:44 EDT Meta Platforms begins trading under symbol 'META' - Shares of Meta Platforms began trading on Nasdaq today under the ticker symbol "META" prior to market open on June 9. This replaces the company's current previous symbol "FB," which has been used since its initial public offering in 2012. "The new ticker symbol aligns with the company's rebranding from Facebook to Meta," the company previously said. Shares of Meta are down $1.13 to $195.51 in morning trading.

09:35 EDT Alkami to offer Array products to client base - Alkami Technology announced a partnership with Array. As part of the partnership, Alkami will offer Array products to Alkami's client base including My Credit Manager, ID Protect and Offers Engine. The Array platform supports financial literacy and offers solutions that help account holders understand, manage and protect their credit. With My Credit Manager, users can receive score change alerts, interact with a score simulator, view credit score factors and debt analysis components. ID Protect includes identity monitoring, insurance and restoration services that help keep users safe from fraud. This includes Dark Web monitoring, alerts and identity theft restoration services.

09:32 EDT Zendesk falls 11% to $71.69 after strategic review ends with no sale

09:31 EDT Aerojet Rocketdyne executive chairman urges shareholders to vote for slate - Aerojet Rocketdyne Holdings Executive Chairman Warren Lichtenstein, who collectively with his affiliates and the participants in his solicitation owns approximately 5.6% of the company's outstanding shares, released a presentation that details the case for new leadership following approximately 18 months of "financial and operational deterioration." The presentation includes CEO candidate Mark Tucker's vision and strategy. As a reminder, Lichtenstein is asking shareholders to vote on the GREEN proxy card to elect his refreshed eight-member slate, which includes himself, Mr. Tucker and six other candidates: Hon. Tina Jonas, Joanne Maguire, Aimee Nelson, Martin Turchin, Vice Admiral Mathias Winter and Heidi Wood.

09:29 EDT Zendesk reached out to 26 parties, received no buyout proposals - Zendesk said in a statement: "At the direction of the Board, Zendesk's financial advisors conducted a comprehensive outreach to 26 potential counterparties, including 16 potential strategic partners and 10 financial sponsors, including a group of investors who had previously expressed conditional interest in acquiring the Company. Over the course of several months, the Company engaged in management meetings and an extensive due diligence process with four potential strategic partners and six financial sponsors. Ultimately, only a subset of the financial sponsors, and none of the potential strategic counterparties, chose to continue in the process. Despite the Company extending the process several times to provide interested financial sponsors additional time and access to attempt to secure sufficient financing, no actionable proposals were submitted, with the final bidders citing adverse market conditions and financing difficulties at the end of the process."

09:20 EDT Humana's onehome announces expansion to Virginia - Humana announced that for the first time, it will bring its onehome value-based home care model to Virginia. onehome, a subsidiary of Humana, will coordinate in-home care services for Humana Medicare Advantage plan members in Virginia, working with existing home care providers in the market. onehome's integrated model creates a single point of accountability that takes into account the needs of patients, physicians, hospitals and health plans for home-based patient care, with that care largely delivered through a network of local home care providers. With the expansion of onehome, Humana plans to add approximately 220 employees in Virginia and North Carolina by the end of 2022, bringing the company's total employment in the region to more than 2,000.

09:20 EDT Bexil Corp announces election of directors, amended bylaws - Each of John Hitchcock and William Winmill were elected to the board of directors of Bexil Corporatio as a Class III Director to serve until the 2025 annual meeting of stockholders, or thereafter when his successor is duly elected and qualifies. This announcement was made at the conclusion of the Company's Annual Meeting of Stockholders on June 7, 2022. The Company announced today that it amended its bylaws effective June 7, 2022.

09:19 EDT Universal Health Realty increases dividend 0.5c to 71c per share - Universal Health Realty voted to increase the quarterly dividend by 0.5c and pay a dividend of 71c per share on June 30 to shareholders of record as of June 20.

09:18 EDT Mawson Infrastructure announces bitcoin miner update - Mawson Infrastructure Group provides an ASIC Bitcoin Miner shipment, deployment and operational update. Mawson has now received the final shipment of A1246 ASIC Bitcoin Miners from Canaan, with the final batch of orders placed in 2021 being deployed across the company's operations in the coming months. Current Bitcoin and broader market movements has seen ASIC Bitcoin Miner pricing fall significantly, placing Mawson in a strong position to acquire new ASIC Bitcoin Miners at attractive prices at the appropriate time. Mawson now has approximately 40,000 ASIC Bitcoin Miners deployed across its Self-Mining and Hosting Co-location business, operating at a combined total of approximately 3.1 Exahash across all operations. Mawson's Hosting Co-location business continues to scale up, with over 56 megawatts rapidly deployed over the last 3 months, providing an additional revenue stream for the company over and above Mawson's Bitcoin Self-Mining operations. Mawson's Australian operations are expected to be fully operational by the end of June, with approximately 5,376 ASIC Bitcoin Miners in place at site, currently operating at 0.2 Exahash, expected to rise to 0.4 Exahash by June 30, producing approximately 1.7 Bitcoin per day from this facility alone based on current network difficulty.

09:17 EDT Oatly introduces electric heavy duty trucks to fleet in North America - Oatly Group announced the introduction of electric powered, heavy-duty trucks to the Company's ground transportation in North America. Finding initial success with utilizing electric trucks as part of the Company's transportation operations in Europe beginning in 2020, Oatly now expands the initiative to include an initial fleet of five electric trucks in the U.S. As part of its ambition to set an example as a future company, Oatly aims to shift to 100% sustainable ground transport for its products and materials by 2029. The introduction of electric trucks within U.S. operations helps build toward this ambition. "Oatly is on a mission to transform the global food system into one that is healthier for people and the planet. A critical part of that system includes the transportation we and the broader food and beverage industry utilize across the supply chain," said Chi Mbachu, VP of Logistics at Oatly, North America. "Any improvements we can make across our business to have less of an impact on the environment, including within our transportation logistics, is a step in the right direction and something we constantly strive for at Oatly. We're thrilled to get these electric trucks on the road in North America and continue our global transition to sustainable ground transportation."

09:17 EDT Better Choice Company reminds shareholders to vote on annual meeting proposals - Better Choice Company is reminding shareholders to vote on the proposals being presented at the upcoming annual meeting of shareholders to be held on Monday, June 13, 2022 by the deadline of 11:59 p.m. ET on Sunday, June 12, 2022.

09:15 EDT ISS recommends Guardion Health Sciences holders vote for Proposal 3 - Guardion Health Sciences announced that independent proxy advisory firm ISS recommends that Guardion stockholders vote in favor of proposal 3 and proposal 4 at the Company's upcoming Annual Meeting of Stockholders on June 16 . Only stockholders of record on the record date of April 18 are eligible to attend and vote on proposals presented at the Annual Meeting. "Your vote " for Proposal 3 at the Annual Meeting of Stockholders on June 16 is critically important. As of the record date, there are 837,989 shares of common stock available for issuance under the 2018 Equity Incentive Plan. Approval of the amendment to the 2018 Equity Incentive Plan will permit the Company to continue to use stock-based compensation to align stockholder and employee interests and to motivate employees providing services to us or any subsidiary. As the Company continues to build out its management team, the Company believes it is critical to emphasize equity compensation to key new employees in order to protect its cash while providing these employees with valuable incentives to help the Company achieves its strategic initiatives," said the company in a statement.

09:14 EDT LPL Financial welcomes Encore Capital Management - LPL Financial announced that Encore Capital Management has joined LPL Financial's broker-dealer and corporate registered investment advisor model, aligning with The Financial Services Network, an existing firm supporting LPL-affiliated advisors. The advisors of Encore Capital reported having served approximately $205 million in advisory, brokerage and retirement plan assets. They join from Wells Fargo Advisors. Through a hands-on and personalized approach, Encore Capital Management works to take the mystery out of investing, insurance, estate planning and wealth preservation for their clients, which include high-net-worth individuals, business owners and families. Based in Glendale, Calif., the team is led by managing partners and co-founders Ara Mekhitarian, CFP, CIMA, and Leonardo Aguilar, CIMA, and supported by chief administrative officer Amanda Aguilar, CFP.

09:11 EDT Ambac's Xchange Benefits signed program manager agreement with Markel Service - Xchange Benefits, a managing general underwriter owned by Ambac Financial Group, announced it has signed a program manager agreement with Markel Service. Under the agreement, Xchange will underwrite medical stop loss coverage on behalf of an insurance affiliate of Markel, as well as handle claims and administer premiums. The collaboration marks Markel's entry into the stop loss segment. "We are honored to be the only company writing stop loss insurance for Markel," Peter McGuire, CEO of Xchange, said. "Xchange's deep expertise in employer stop loss and Markel's network of producers position us well to take advantage of the growth opportunities that exist in this line of business. We look forward to a long and successful collaboration with Markel."

09:10 EDT Marriott Vacations CEO Stephen Weisz to retire, John Geller, Jr to succeed - Marriott Vacations Worldwide announced that after 50 years of dedicated service in the hospitality and travel industry, Stephen Weisz informed the company's Board of Directors of his intent to retire as CEO at the end of the company's fiscal year on December 31, 2022. The company also announced current President, John Geller, Jr., will succeed Steve and assume the role of President and CEO, effective January 1, 2023. Steve has served in senior leadership roles for the last 26 years, first as President of Marriott Vacation Club International, a division of Marriott International, and the last 10 years serving in the role of Chief Executive Officer, Marriott Vacations Worldwide, which became a publicly traded company in 2011.

09:09 EDT Teradata accelerates scalability of AI/ML projects with Amazon SageMaker - Teradata (TDC) announced the integration and general availability of the Teradata Vantage multi-cloud data and analytics platform with Amazon (AMZN) SageMaker. "By uniting the scalability and openness of Vantage with the intuitive ML model capabilities of Amazon SageMaker, Teradata and Amazon Web Services are solving the scalability dilemma for enterprises worldwide," the company said. "Our enterprise customers are investing in the possibility of AI/ML to prevent fraud, reduce churn, optimize supply chains, and prevent catastrophic infrastructure failures," said Hillary Ashton, Chief Product Officer at Teradata. "Many technology providers claim to offer AI/ML solutions to meet these critical needs - but they cannot implement them at scale. Teradata is, and always has been, an innovator in enterprise analytics and data warehousing, solving the toughest data challenges in the most complex and demanding environments. Now we are combining Vantage's flexibility, scalability, and deep advanced analytics capabilities with Amazon SageMaker's versatility in creating ML models to give enterprises the speed, simplicity, and scale they need to derive genuine business value from their AI investments."

09:06 EDT Maris-Tech gets $300,000 purchase order from Israeli defense company - Maris-Tech announced it has received a $300,000 purchase order from a leading Israeli defense company. The purchase order refers to Maris-Tech' Opal platform, which is based on its advanced Jupiter AI platform. "We have seen an increase in demand for our unique products and technologies over the past few months, resulting in new orders and partnerships," said Israel Bar, CEO of Maris-Tech. "Our technology platform enables us to adapt our solutions to the needs of our customers and as a result, expand our product portfolio. We enjoy a high level of confidence from leading players in the defense and surveillance sector, contributing greatly to our reputation and our recognition in the market".

09:05 EDT Senmiao Technology reports May operating metrics for ride-hailing platform - Senmiao Technology reported operating metrics for its proprietary online ride-hailing platform for May 2022. In May 2022, Senmiao and its affiliates reported over 0.93 million total completed orders, a 7.8% increase from approximately 0.87 million total orders completed in April 2022. The number of drivers completing rides via the platforms - Active Drivers - in May 2022 was 5,989, down approximately 1.7% from 6,095 in April 2022.

09:04 EDT Iroquois Capital urges PharmaCyte Biotech to 'reconstitute the Board' - Iroquois Capital Management, one of the largest stockholders of PharmaCyte Biotech, with beneficial ownership of approximately 5.8% of the outstanding common stock of the company, announced that it has delivered a letter to the company's Board of Directors. The letter stated, in part, "We appreciate that much of the company's upcoming milestones are largely determined by the lifting of the FDA's hold on the company's Phase 2b clinical trial, whose timeline continues to drift further into the future and is largely outside of the company's control, however we think the company's recent announcements provide a glimpse into the positive change an independent and highly experienced Board is capable of effecting in short order to the extent its interests are aligned with the company's stockholders. Accordingly, we hereby reiterate our request for the company to immediately enlist the participation of its stockholders in a process to meaningfully reconstitute the Board with highly qualified nominees possessing the requisite experience and ownership mentality required to drive the level of change we believe is necessary to create value at the company. Barring the foregoing, we intend to provide stockholders the option to select a different path for the future of their company and to allow their collective voice be heard at the upcoming annual meeting scheduled for August 25, 2022."

09:04 EDT D-Orbit signs EUR 1,950,343 contract with the European Space Agency - D-Orbit, the space logistics and transportation company that is going public through a transaction with Breeze Holdings Acquisition has signed a EUR 1,950,343 contract with the European Space Agency under BOOST, the Agency's Commercial Space Transportation Services and Support to Member States Programme. The sum represents 80% of the total budget of the activities to be carried out in the frame of the contract. Through this contract ESA will provide funding for the development of an improved production system by introducing lean manufacturing principles and testing that will enable D-Orbit to increase the performance and responsiveness of its proprietary orbital transfer vehicle ION Satellite Carrier while driving down the cost. The contract also anticipates the improvement of various subsystems, including those involved in orbital maneuvering. Since September 2020, D-Orbit has successfully operated six orbital transportation missions, with three more planned for the remainder of 2022, and 13 scheduled for 2023.

09:03 EDT Sodexo launches new Everyday mobile app - Sodexo announced the launch of Everyday, the company's new mobile commerce solution. Customers at Sodexo client sites will now enjoy features including mobile and kiosk ordering, digital wallet, personalization, scan-and-go capabilities and delivery for customers across the nation. The new technology is set to roll out on campuses this fall. Sodexo's other segments, including Healthcare, will also see the new app by the end of 2022.

09:02 EDT Zynex approves $10M share buyback program - Zynex approved a program to buy back $10.0M of the company's common stock. The program will commence on June 10, 2022 and is scheduled to terminate on June 9, 2023 or when the $10.0M buyback limit is reached. The company fully utilized the $10M buyback announced in April in less than fifty days. This program does not obligate the ompany to acquire any particular amount of common stock, and the program may be suspended or discontinued at any time. The company expects to finance the purchases with existing cash balances, which is not expected to have a material impact on capital levels. Zynex had approximately 41.6 million shares issued and 38.5 million shares outstanding as of June 8.

08:53 EDT Rubicon announces nomination of Barry Caldwell to post-combination board - Rubicon Technologies (RBT) announced the nomination of Barry Caldwell, former Waste Management (WM) Chief People Officer, for election to its Board of Directors upon the closing of the Company's previously announced business combination with Founder SPAC (FOUN). Caldwell currently serves as a principal at Wroxton Civic Ventures, a Washington, D.C.-based advisory services concern.

08:50 EDT Recruiter.com hosts webinar with partner Deel - Recruiter.com Group announced its upcoming webinar with its partner, Deel. Recruiter.com's Vice President of Enterprise Sales, Jennifer Goodfriend, and Deel's Head of People, Casey Bailey, will come together to discuss new hiring trends brought about as a result of a predominantly remote working environment.

08:48 EDT Integrated Media Technology to develop halal product channel in Thailand - Integrated Media Technology's subsidiary World Integrated Supply Ecosystem, or WISE, has entered into a memorandum of understanding with Central Islamic Council of Thailand - CICOT -, the Halal Standards Institute of Thailand and the Halal Science Center Chulalongkorn University Thailand, to establish a strategic partnership to collaborate in Halal affairs including establishing standards, inspection, certification, Halal forensic science laboratory and research exchanges. The Thailand Partners are to actively provide and assist WISE to procure Halal products in Thailand. The parties will also actively develop innovative online cooperation to promote Halal products through online platform events and trade promotions, as well as on organizing joint academic events such as online training courses, conferences and seminars.

08:47 EDT Jaguar Health, Filament Health enter LOI to develop botanical prescription drugs - Jaguar Health and Filament Health announced that the companies have signed a letter of intent to enter a collaboration agreement to develop botanical prescription drugs for specific psychoactive target indications in the United States. The goal of the collaboration is to extend the botanical drug development skillsets of both companies in order to develop pharmaceutical-grade, standardized drug candidates and partner with a potential future licensee regarding the development and commercialization of these novel plant-based drugs for indications such as attention-deficit/hyperactivity disorder and social anxiety disorder. Under this partnership, Jaguar will have responsibility for the identification of plants that may offer novel mechanisms of action, as well as for botanical drug development and the raw material supply chain. Filament will be responsible for developing the manufacturing techniques required to produce standardized, pharmaceutical-grade drug candidates. The two companies will then jointly seek partnership with a potential licensee for full development and commercialization of novel drug candidates, with proceeds from the relationship split equally between Jaguar and Filament.

08:45 EDT Aptevo announces preliminary remission data from Phase 1b APVO436 trial - Aptevo Therapeutics announced new remission data on four additional patients. The new data includes one patient who achieved a complete remission, one patient who achieved a complete remission with incomplete hematologic recovery and two patients who achieved bone marrow complete remissions, or morphological leukemia-free state, in the Company's on-going multi-cohort, multi-center Phase 1b expansion trial evaluating APVO436 for the treatment of acute myeloid leukemia. The Company also provided an update on a myelodysplastic syndrome patient from the dose escalation part of the trial. Cohort 1 currently has the highest enrollment rate in the trial and preliminary data show that a total of four out of 11 response-evaluable patients reported on to date, have experienced remission while on therapy. Of the three new cohort 1 patients announced today, one is a CR, one is a CRi, and one is a bone marrow complete remission. Cohort 1 is a combination arm of the trial that includes relapsed patients and those with primary refractory AML that failed to respond to frontline standard induction chemotherapy. Cohort 1 patients receive standard chemotherapy drug cytarabine or the standard chemotherapy triple drug combination MEC plus APVO436. The fourth new patient reported on today participated in cohort 3, a monotherapy arm of the trial, and achieved a bone marrow complete remission. The Company also announced that a patient with high-risk myelodysplastic syndrome enrolled in the dose escalation trial remains stable and continues treatment with APVO436 now exceeding 18 months. Prior to joining the trial, this patient received and failed treatment with a hypomethylating agent, a situation that is commonly expected to be a poor prognostic event associated with short survival probability of approximately four to six months.

08:41 EDT Amedisys releases inaugural ESG Report - Amedisys has released its first Environmental, Social and Governance Report for the year 2021, detailing actions, achievements and goals in each critical area. "We are in the early stages of mapping our progress with the goal of being a good corporate citizen and to act responsibly in the way we treat our patients, our employees, our communities and the environment that we all share," stated President and CEO Chris Gerard. "We wholly embrace our responsibility to advance social and environmental causes for the betterment of our communities and commit to operating with the highest standards of compliance and ethics." Amedisys participated in an ESG materiality assessment with independent consultants to identify key topics and areas of opportunity to begin tracking and reporting on key performance indicators for each. A newly formed ESG committee, comprised of executives and senior management, will develop, implement and monitor these initiatives and policies.

08:39 EDT II-VI reduces global carbon footprint with renewable energy - II-VI announced that it has signed renewable energy contracts for powering multiple sites throughout Asia with 100% renewable electricity. These new agreements represent 35 GWh of renewable electricity per year, thereby avoiding an additional 18,000 metric tons of CO2 emissions annually. The agreement covers II-VI sites in India, the Philippines, Vietnam, China, and Japan. II-VI has set as a top priority to reduce its carbon footprint across its global operations. Including today's announcement, II-VI has entered into renewable electricity contracts for over 40 sites around the world, including over 35 sites that now cover 100% of their annual electricity usage with renewable sources. "II-VI now purchases approximately 38% of our electricity from renewable sources," said Tim Challingsworth, Chief Sustainability Officer. "This announcement is an important next step in fulfilling our commitment to steadily reduce our carbon footprint position around the globe."

08:38 EDT Iteris' ClearGuide SaaS solution selected by SDOT - Iteris announced that it has been awarded a contract from the Seattle Department of Transportation, SDOT, for a smart mobility, safety and sustainability program, representing the expansion of Iteris' software-as-a-service, SaaS, solutions in the Pacific Northwest. Under the terms of the agreement, Iteris is providing its ClearGuide SaaS solution that enables visualization of traffic data and analysis to improve mobility, safety and sustainability for Seattle road users. SDOT is using ClearGuide features, including: dynamic maps to support detailed traffic analysis; features to help identify and mitigate congestion; animations to analyze events and optimize response plans; historical trend reports and dynamic congestion charts to track reliability and support planning; and APIs to share this information with other tools, and populate the travel times on the dynamic messaging signs of SDOT and partner agencies, including Washington State DOT. "We are thrilled to be able to support SDOT's goal of better managing its transportation network by providing critical mobility intelligence for arterials, highways and citywide speeding hotspots," said Scott Perley, vice president, customer experience and analytics at Iteris. "ClearGuide enables users to receive regular, proactive recommendations through an intuitive user interface and interactive map to improve mobility, safety and sustainability throughout complex transportation networks."

08:37 EDT PPL Corp. increases common stock dividend to 22.5c from 20c per share - PPL Corporation updated its quarterly dividend to reflect the acquisition of Rhode Island Energy. PPL declared a quarterly common stock dividend of 22.5c per share, payable July 1 to shareowners of record as of June 21. This is an increase from the 1Q22 dividend of 20c per share.

08:36 EDT PPL Corp. management to provide update on strategic financial targets - PPL management outlines financial targets and vision for new PPL: a premier U.S. regulated utility Top-tier earnings and dividend growth to be fueled by $27 billion of investment opportunities through 2030, superior operating expertise and one of the strongest balance sheets in the U.S. utility sector. Forward-looking investments and strong focus on technology and innovation underpin strategy to advance cleaner, reliable, affordable energy and drive significant, sustainable value creation. PPL Corporation will host a virtual Investor Day during which management will provide an update on the company's strategy to deliver growth and a clean energy future. PPL's leadership team will discuss the company's: strategic shift into a large-cap U.S. regulated utility company operating in constructive regulatory jurisdictions - Kentucky, Pennsylvania and Rhode Island; top-tier projected EPS and dividend growth of 6% to 8% annually, culminating in an annual 9% to 11% total return proposition; robust capital investment plan, including $27B of regulated investment opportunities through 2030 to advance grid modernization, grid resiliency and cleaner energy to best serve our customers; improved balance sheet to support the company's growth with no equity issuances; opportunity to transition its coal-fired generation fleet in Kentucky in support of PPL's goal of net-zero carbon emissions by 2050. The company also updated its quarterly dividend to reflect the acquisition of Rhode Island Energy. PPL declared a quarterly common stock dividend of 22.5c per share, payable July 1 to shareowners of record as of June 21. This is an increase from the Q1 dividend of 20c per share.

08:35 EDT First Solar's Ohio complex achieves Platinum status in RBA VAP audit - First Solar announced that its 2.7 gigawatt DC vertically integrated manufacturing complex in Ohio has achieved Platinum status in a Responsible Business Alliance Validated Assessment Program audit. Platinum is the highest possible rating awarded on completion of a full VAP audit, which is considered a leading standard for onsite compliance verification and effective, shareable social and environmental audits across industries. The audit was conducted at First Solar's manufacturing facilities in Perrysburg and Lake Township, Ohio, by independent third-party auditors specially trained in social and environmental auditing and the VAP audit protocol. It covered the full scope of the VAP, including fair labor practices and human rights, health and safety measures, environmental performance, business integrity, ethics, and supporting management systems. The rating is valid until May 5, 2024.

08:34 EDT Save Foods says SaveProtect Organic treatment becomes OMRI-listed - Save Foods announced that its SaveProtect Organic crop treatment for extending the shelf-life of fresh fruits and vegetables has been listed by the Organic Materials Review Institute, an international non-profit organization that provides an independent review of products that are intended for use in certified organic production and processing. OMRI Listed products may be used in certified organic production and processing under the USDA National Organic Program.

08:33 EDT IAA announces opening of Bristol branch in the UK - IAA and its subsidiary, SYNETIQ, announce the opening of a full-service facility in Bristol, located in the southwest region of the UK. The Bristol site will greatly increase the company's capacity and enable it to meet the growing needs of current and new customers. "The new branch in Bristol is vital to our ongoing expansion in the UK," said Tom Rumboll, UK Managing Director for IAA and CEO of SYNETIQ. "Our new strategically located, 22-acre investment - which is licensed by the Environmental Agency - will contribute significantly to our sustainability goals in the country by increasing efficiency and reducing miles driven. We are excited to bring our combined company's signature customer service and modern technology to the area and look forward to its success."

08:32 EDT Nikola's Tre BEV approved for New York Truck Voucher Incentive Program - Nikola announced that its Nikola Tre battery-electric vehicle has been deemed eligible for the New York Truck Voucher Incentive Program. NYTVIP provides vouchers, or discounts, to fleets across New York State that purchase or lease medium- and heavy-duty zero-emission battery electric vehicles. With this approval, purchasers of the Nikola Tre BEV can now qualify for an incentive valued at up to $185,000 per truck, with a scrappage requirement.

08:28 EDT DavidsTea launches Manoomin Maple in partnership with Tea Horse - DAVIDsTEA is pleased to announce the launch of their new blend Manoomin Maple, in partnership with fellow tea company Tea Horse, now available at all 18 DAVIDsTEA flagship stores across Canada, and online at davidstea.com. DAVIDsTEA is proud to share that 10% of all proceeds from Manoomin Maple will go towards the David Suzuki Institute to support Indigenous communities through the Reconciling Ways of Knowing program.

08:27 EDT Lundbeck to present data on VYEPTI at Annual Scientific Meeting of the AHS - Lundbeck announced data on VYEPTI will be presented at the 64th Annual Scientific Meeting of the American Headache Society, AHS, taking place from June 9-12, 2022. A total of nine poster presentations will be shared to highlight clinical data and real-world analyses of eptinezumab as a preventive migraine treatment in adults. Key abstracts include: Treatment with eptinezumab resulted in downward shift in diagnostic frequency category: A post-hoc analysis of the Phase 3 studies of eptinezumab for migraine prevention in adults with episodic or chronic migraine looked at the proportions of patients with a reduction from baseline of headache frequency following the first 6 months of treatment with eptinezumab. In both PROMISE-1 and PROMISE-2 studies, treatment with eptinezumab resulted in a sustained downward shift in diagnostic frequency of episodic and chronic migraine across two dosing intervals. Subsequent dose of eptinezumab showed benefit for patients initially reporting suboptimal response: A post-hoc analysis of the pivotal Phase 3 PROMISE-1 and PROMISE-2 studies assessed predictors of a second-dose response to eptinezumab treatment for the prevention of migraine over weeks 13-24 in patients who initially reported a suboptimal first-dose response to eptinezumab over weeks 1-12. The analysis showed in both PROMISE studies, a second dose of eptinezumab may be beneficial for patients with episodic or chronic migraine who did not experience greater than or equal to50% reduction in MMDs with their first dose of eptinezumab. The proportion of suboptimal first-dose responders who were second-dose responders was 37.0% with eptinezumab and 33.9% with placebo in PROMISE-1, and 28.8% with eptinezumab and 18.5% with placebo in PROMISE-2. Migraine Prevention in Patients with Prior Treatment Failures: This exploratory subpopulation analysis of the Phase 3b DELIVER study evaluated the efficacy and safety of eptinezumab for the prevention of migraine in patients with 2-4 previous preventive treatment failures. Patients treated with eptinezumab demonstrated larger reductions in MMDs from baseline through week 12 than patients receiving placebo across all subgroups. Mean MMDs for patients with episodic migraine decreased by 3.1 days and 4.0 days versus 1.0 day for placebo. For patients with chronic migraine, mean MMDs decreased by 6.5 day and 6.6 days versus 3.3 days for placebo. And, for patients with medication overuse headache, mean MMDs decreased by 5.6 days and 7.3 days versus 2.3 days.

08:27 EDT Aemetis connected its third anaerobic digester via pipeline to RNG gas cleanup - Aemetis announced that its wholly owned subsidiary, Aemetis Biogas, connected its third anaerobic digester via pipeline to the company's main RNG gas cleanup unit located at the Aemetis Advanced Fuels Keyes facility in Keyes, California. Aemetis remains on track to complete an additional five digesters by the end of Q4 2022, with five more digesters under construction in the same timeframe."Connecting our growing network of dairy digesters will accelerate the pace of Greenhouse Gas reduction in California," said Andy Foster, President of Aemetis Biogas. "Because dairy-based Renewable Natural Gas has a negative Carbon Intensity capturing unmitigated methane from dairies such as Ahlem Jerseys accelerates our ability to provide negative carbon transportation fuel to RNG customers in California to replace diesel in trucks and buses," added Foster. The Aemetis Central Dairy Digester project is designed to capture and convey conditioned biogas from more than 60 dairies to the Company's centralized gas cleanup facility which is operational at the Aemetis Advanced Fuels Keyes ethanol plant. The RNG is either delivered into the PG&E utility pipeline located onsite at the Aemetis ethanol plant, or dispensed to trucks at the RNG fueling station being built at the Aemetis plant, or used as process energy in the Aemetis facility to replace petroleum-based natural gas. The Ahlem Farms Jerseys dairy digester was funded in part by a $1.4M grant from the California Department of Food and Agriculture CDFA. The $12M biogas cleanup facility was funded in part by a $4.2M grant from the California Energy Commission CEC.

08:24 EDT Impel Pharmaceuticals to present Trudhesa data at AHS meeting - Impel Pharmaceuticals announced that it will present one oral presentation and three poster presentations from the pivotal, 52-week long, open-label, Phase 3 STOP 301 trial exploring the safety and exploratory efficacy of Trudhesa nasal spray, at the 64TH Annual American Headache Society Scientific Meeting, taking place June 9-12, 2022, in Denver, Colorado. Sara Sacco, M.D., a neurologist with the Carolinas Headache Clinic, Charlotte, North Carolina, and lead author on the prediction of response analysis abstract, will present an American Academy of Neurology encore analysis from the pivotal, Phase 3 STOP 301 trial, aimed to determine if early treatment response to Trudhesa could predict response over consecutive migraine attacks. Using Impel's proprietary Precision Olfactory Delivery technology, Trudhesa delivers dihydroergotamine mesylate -a proven, well-established therapeutic for the acute treatment of migraine for adults-quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and reduces potential absorption issues, offering rapid, sustained, and consistent symptom relief without nausea commonly associated with older migraine medications, even when administered outside the traditional window of efficacy for a migraine attack. Drug delivery via the POD technology enables rapid absorption and provides enhanced bioavailability and reaches intravenous-like systemic levels quickly, which could transform the treatment landscape. Oral Presentation: The analysis that Dr. Sacco will discuss found that patients who self-report mild or no pain at two hours for their first three Trudhesa-treated migraine attacks are extremely likely to respond to Trudhesa treatment. Those with no or mild pain for their first two Trudhesa treated migraine attacks were also likely to respond to Trudhesa treatment. Results suggest that if Trudhesa provides pain relief for the first two to three migraine attacks, it is likely a patient will respond to Trudhesa with long-term use, which is informative for clinical decision making. Poster Presentations: This analysis looked to determine report scores for each item of the Migraine Disability Assessment Scale questionnaire following long-term use with Trudhesa for the acute treatment of migraine. The review suggests that long-term treatment with Trudhesa was associated with improvements in scores of several individual MIDAS items of productivity and disability, as well as a decrease in the number of headache days over 24 and 52 weeks, leading to a reduction in overall patient burden. Presentation Title: "Improvements in Productivity and Disability with INP104 as Assessed by the Migraine Disability Assessment Scale: Results from the Phase 3 STOP 301 Study"; Poster #P-176 This analysis evaluated data from the STOP 301 trial to determine the efficacy of Trudhesa in patients who did or did not use concomitant migraine preventive medications over 24-week period. Treatment with Trudhesa over 24 weeks demonstrated improvements in self-reported pain and most bothersome symptom freedom at 2 hours post-Trudhesa with most of the concomitant migraine preventive groups analyzed. Results suggest that Trudhesa may be an effective acute therapy for migraine in patients who are concurrently using preventive therapies. Presentation Title: "Exploratory Efficacy of INP104 in Patients Using Concomitant Preventive Migraine Medications"; Poster #P-174 An additional AAN encore presentation from the pivotal, Phase 3 STOP 301 trial, will look at the exploratory efficacy of Trudhesa treatment over 24 weeks based on acute medications used prior to Trudhesa. There are many evidence-based migraine acute treatments currently available and these are either migraine non-specific or migraine-specific. Since there are numerous acute therapies available, it is important to determine if the efficacy of Trudhesa is impacted by prior acute treatment history. Acute therapies most commonly used prior to initiation of treatment with Trudhesa were acetaminophen, NSAIDs, and triptans. This analysis suggests that Trudhesa is an effective treatment for migraine patients who have previously used a variety of acute therapies. Presentation Title: "Exploratory Efficacy of INP104 in Migraine Patients by Prior Treatment"; Poster #P-173

08:22 EDT Teva announces results from US retrospective study on use of AJOVY injection - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced results from a U.S. retrospective study examining real-world concomitant use of AJOVY injection and gepants in the prevention and acute treatment of migraine. The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 American Headache Society, AHS, Annual Meeting held June 9-12, 2022, in Denver, Colorado. Data presentations at AHS included eight abstracts examining real-world use of AJOVY across different patient populations and clinical circumstances. In an additional poster presentation, results of a subgroup analysis from the Phase 3b FOCUS study examining the use of AJOVY in patients with difficult-to-treat migraine and comorbid obesity were reported. Real-World Effectiveness and Tolerability of Fremanezumab for the Preventive Treatment of Migraine in Patients Using Concomitant Gepants for Acute Treatment in a US Neurology Practice: The US retrospective chart review study examined data from electronic medical records of 55 adult patients from the Dent Neurologic Institute, a multi-location practice in New York, who used AJOVY for preventive migraine treatment and concomitant gepants for acute migraine treatment between January 1, 2020 and May 1, 2021. Data were collected on patients with chronic and episodic migraine. Patients were on a gepant therapy for one or more months pre- and post-initiation of AJOVY as add-on therapy. Patients with three or more measurements of monthly migraine days were included in the analysis: one at the pre-index date, one at index, and one at the post-index period. At the time of AJOVY initiation, patients had an average of 15.8 MMD. The average time from the index date to the last visit was 9.4 months. The average change in MMD from the index to the post-index date was -6.5 days, representing a 41.1% reduction. Five patients had adverse events post-index; 3 injection site reactions, 1 uveitis and 1 upset stomach.

08:21 EDT Farmers & Merchants set to join Russell 3000 Index - Farmers & Merchants Bancorp is set to join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022, according to a preliminary list of additions posted June 3.

08:20 EDT Sono-Tek expected to be added to Russell 3000 Index - Sono-Tek Corporation announced that it expects to join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell Index annual reconstitution on June 27, 2022, according to the preliminary list of additions posted by FTSE Russell.

08:19 EDT Annaly Capital publishes third corporate responsibility report for 2021 - Annaly Capital Management announced the publication of its third corporate responsibility report for the year 2021, titled Taking Stock of Our Impact. "As outlined in our report, we continue to Take Stock of Our Impact - establishing ESG goals and commitments and tracking our considerable progress as we strive to integrate ESG priorities across our business," said David Finkelstein, Annaly's Chief Executive Officer and President. "I am pleased to share all that we have accomplished in 2021, including enhancing the Company's executive compensation program, expanding our parental leave and fertility benefits and providing additional climate-related disclosures. These and our other ESG milestones have helped create durable value for all of our stakeholders."

08:18 EDT ChargePoint partners with NECA to accelerate deployment of EV charging - ChargePoint announced a new partnership with the National Electrical Contractors Association, NECA, the voice of the $202B electrical construction industry with 118 local chapters, to accelerate the deployment of EV charging. Through the partnership, ChargePoint and NECA will develop training programs for its electrical contractor members who install EV charging infrastructure and be a resource in NECA's Industry Alliance Network, IAN, which connects NECA contractors to companies at the forefront of the electrical industry. "At NECA, a key value we provide is connecting our members with the products and services that are leading our industry," said NECA CEO David Long. "The Industry Alliance Network opens new avenues to deepen the conversation between these brands and NECA contractors. It is NECA National's goal to provide solutions with increased access and attention within our industry."

08:17 EDT AgileThought announces launch of eight technology guilds - AgileThought announces a new delivery model that will accelerate digital transformation strategies for enterprises with an agile approach to discover, design, and deliver on digital strategic initiatives, at speed. AgileThought is supporting this new delivery model through the formation of eight "Guilds" designed to help extend market leadership, drive significant value for all clients, and provide high-growth career paths for our employees. The Guilds are distinct groups with domain experience embedded in their areas of expertise, working cross-functionally in fast-moving teams called Agile Squads to drive innovation and establish new offerings and solutions for our clients. To start, the eight Guilds include: Data & AI, Enterprise Solutions, Front-end Engineering, Cloud Platforms and Back-end Engineering, Quality, Design & Product, Cloud Operations and Cybersecurity, and Agility. AgileThought is making these changes at a time of rapid growth and digital disruption in the market. For companies to survive in this more digitally-focused business landscape, they need world-class talent with an agile culture capable of adopting new technologies quickly to drive innovation forward. The combination of deep domain expertise, a proven agile methodology, and immersion in the most cutting-edge technologies are core to the Guild structure. This allows for better, clearer, and more attractive opportunities for current and future employees to grow and fuel continuous innovation for AgileThought's clients. With our new collaborative delivery model, new offerings and points of views on digital trends are developed quicker, and business and delivery teams are better able to work cross-functionally with clients anywhere in the world.

08:15 EDT Cheniere Energy, Equinor sign long-term LNG sale, purchase agreement - Cheniere Energy (LNG) announced today that its subsidiary, Cheniere Marketing, has entered into a liquefied natural gas, LNG, sale and purchase agreement, SPA, with Equinor ASA (EQNR). Under the SPA, Equinor has agreed to purchase approximately 1.75M tonnes per annum of LNG from Cheniere Marketing on a free-on-board basis for a term of approximately 15 years. The deliveries under the SPA will start in the second half of 2026 and reach the full 1.75 mtpa in the second half of 2027. Jack Fusco, Cheniere's President and Chief Executive Officer said, "This SPA further reinforces Cheniere's leadership in providing the flexible, reliable and cleaner burning long-term LNG supply sought by our customers across the globe focused on energy security and environmental priorities."

08:13 EDT Schneider Electric launches inaugural Global Partner Recognition Program - Schneider Electric announced the launch of the inaugural Schneider Electric Sustainability Impact Awards, the first initiative from the Partnering for Sustainability Program, to recognize the critical role that Schneider's partners play in delivering a more resilient and sustainable electric world. The Partnering for Sustainability program is a continuation of Schneider's initiatives to empower its extensive ecosystem of partners to move toward a more sustainable future. It includes comprehensive education and training, a simplified product portfolio, an open and collaborative support ecosystem and access to expertise and resources on digital transformation. Designed to empower partners to become more sustainable in their own practices and support their customers on the path to net-zero, the program provides four easy steps that partners can follow to future-proof their businesses.

08:12 EDT Fleetwood Homes provides showcase home for 'Homes on the Hill' event - Fleetwood Homes announced that its Rocky Mount, Virginia, production facility has built, transported and staged one of the three manufactured homes appearing on the National Mall in Washington, D.C. this week in support of the Manufactured Housing Institute's "Homes on the Hill" advocacy initiative. In collaboration with the Innovative Housing Showcase hosted by the U.S. Department of Housing and Urban Development, "Homes on the Hill" is making an inspired return to the capital from Tuesday, June 7 to Sunday, June 12, and representatives from Fleetwood Homes and Cavco are there to support this important effort. After being sidelined by the pandemic since the 2019 inaugural event, MHI will once again showcase the compelling value of manufactured homes to policymakers, affordable housing influencers and supporters, the media and consumers.

08:10 EDT ReTo Eco-Solutions receives Nasdaq minimum bid price deficiency notification - ReTo Eco-Solutions received a written notification from Nasdaq on June 3, notifying the company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. The letter does not impact the company's listing on Nasdaq at this time. The company has been provided 180 calendar days, or until November 30, to regain compliance. The ompany may be eligible for additional time to regain compliance or may face delisting. The company intends to monitor the closing bid price of its common shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding common shares, to regain compliance.

08:09 EDT Eledon Pharmaceuticals announces orphan drug designation for tegoprubart - Eledon Pharmaceuticals announced that the U.S. Food and Drug Administration has granted orphan drug designation to tegoprubart for the prevention of allograft rejection in pancreatic islet cell transplantation. Tegoprubart previously received orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis/ Pancreatic islet cell transplantation requires immunosuppressive therapy to protect transplanted cells from immune rejection. Adoption of islet cell transplantation as a treatment option for type 1 diabetes has been hampered, in part, by the toxicity associated with part of the current immunosuppressive standard of care, calcineurin inhibitors. CNIs are required to prevent transplanted islet cell rejection yet result in acute islet cell dysfunction and loss. CNI-associated islet cell dysfunction and loss can result in the need for multiple islet cell transplant procedures to achieve optimal glucose control and potentially eliminate the need for exogenous insulin. Tegoprubart is in a Phase 2a clinical study for the prevention of allograft rejection in pancreatic islet cell transplantation as part of a CNI-free immunosuppressive regimen.

08:08 EDT Mayfair Gold announces flow-through financing - Mayfair Gold Corp. announced a strategic financing to further the successful exploration program at the Fenn-Gib gold project in the Timmins region of Ontario. The Company intends to issue 4,300,000 common shares of the Corporation on a flow-through basis at a price per share of $1.63 by way of a non-brokered private placement. The Offering Price represents a premium of 36% over the closing price of Mayfair Gold common shares on the TSX.V on June 8, 2022. The gross proceeds from the sale of FT Shares will be used for expenditures which qualify as Canadian Exploration Expenses within the meaning of the Income Tax Act. The Company will renounce such CEE expenditures with an effective date of no later than December 31, 2022. The Common Shares issued will be subject to a four month hold period. The Offering is expected to close on or before June 30, 2022, and is subject to customary closing conditions, including approval from the TSX.V. A finder's fee may be paid on a portion of the Offering.

08:07 EDT Amcor names Susana Suarez Gonzalez as Chief Human Resources Officer - Amcor (AMCR) announced the appointment of Susana Suarez Gonzalez as Executive Vice President and Chief Human Resources Officer, effective June 13. She will be responsible for leading Amcor's global human resources function, with a strong focus on continuing to invest in talent and organizational development as levers for delivering strategy and growth. Suarez Gonzalez will report to Ron Delia, Amcor's CEO. Suarez Gonzalez brings more than 31 years of human resources experience, driving talent and growth in business-to-business organizations. Her most recent role was as Executive Vice President, Chief Human Resources and Diversity & Inclusion Officer at International Flavors and Fragrances (IFF).

08:07 EDT Enphase Energy expands IQ8 Microinverter deployments in Southern California - Enphase Energy announced that installers of Enphase products in Southern California have seen growing deployments of Enphase Energy Systems powered by IQ8 Microinverters following the product's launch in North America late last year. IQ8 Microinverters paired with Enphase's IQ Batteries gives homeowners more energy independence and peace of mind as power supply shortages are predicted to lead to blackouts across the state this summer.

08:06 EDT United Dairy Farmers picks Mobivity's SmartMessage for customer engagement - Mobivity Holdings announced that United Dairy Farmers has selected Mobivity's SmartMessage to launch its text club across all locations to engage with guests who opt-in to receive text messages and increase enrollment of its U-Drive loyalty program.

08:05 EDT Seelos Therapeutics' SLS-004 shows significant efficacy in dementia - Seelos Therapeutics announced data demonstrating a statistically significant - pless than0.01 - 19% downregulation of mRNA and a ~40% reduction of alpha synuclein in an in vitro study of SLS-004, its gene therapy program utilizing CRISPR-dCas9, in dementia with Lewy bodies, or DLB. DLB is characterized by the accumulation of aggregated alpha-synuclein protein in Lewy bodies and Lewy neurites. Seelos plans to advance into additional preclinical studies in DLB and Parkinson's and expects additional data in the second half of this year. Seelos plans to advance the study of SLS-004 in DLB in additional preclinical studies and disclose further developments of this new CRISPR-based therapeutic technology in the future. In July 2021, Seelos released positive preclinical in vivo data with SLS-004 in downregulation of overexpressed alpha-synuclein in a Parkinson's disease model and plans to release additional data in the second half of 2022.

08:04 EDT Tempest Therapeutics expects cash to fund plans into 1Q24 - Following the $15 million private investment in public equity financing completed in April 2022, Tempest's cash and cash equivalents are currently expected to be sufficient to fund its current operating plans into the first quarter of 2024.

08:03 EDT Tempest Therapeutics provides ASCO KOL feedback on TPST-1120 results - Tempest Therapeutics summarized key takeaways from the TPST-1120 clinical program provided by Mark Yarchoan, M.D., associate professor of oncology at Johns Hopkins School of Medicine, at its June 5th investor event held in connection with the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, IL. The company also revised its cash guidance. Dr. Yarchoan also presented the TPST-1120 Phase 1 results in an oral presentation at ASCO on Tuesday, June 7. Dr. Yarchoan reviewed and discussed TPST-1120 results both as a single agent and in combination with nivolumab in a webcast presentation. His conclusions include: The monotherapy arm consisted of one of the more challenging groups of tumors to treat in a Phase 1 trial, e.g., dominated by patients with late-line pancreatic and cholangiocarcinoma, where he considered stable disease a "win." A number of patients in the monotherapy arm had meaningfully-prolonged stable disease, showing that TPST-1120 has activity as a monotherapy; Two patients with IDH1 mutated CCA, a mutation found in ~15-30% of intrahepatic CCA, had stable disease extending out to five and ten months, respectively, vs. less than three months for historical standard-of-care values, indicating that an IDH1 mutation is a potential biomarker for patient sensitivity to TPST-1120; In the combination arm, two patients with renal cell carcinoma and one with metastatic CCA achieved partial response when treated with the higher doses of TPST-1120 in combination with pembrolizumab; Both RCC patients had progressed on prior anti-PD1 therapy, providing strong evidence that TPST-1120 overcomes resistance to anti-PD1 therapy; The patient with metastatic CCA had received multiple lines of prior systemic therapy and was PDL1-negative, mismatch repair proficient, and had a TMB of less than 10 mutations per megabase, supporting that TPST-1120 can reprogram the TME in immune-resistant type cancers. TPST-1120 Monotherapy Results: In the monotherapy portion of the trial, 19 evaluable patients with late-line treatment-refractory solid tumors, including pancreatic, cholangiocarcinoma, and colorectal cancers, were treated with oral twice-daily TPST-1120. The results showed that 53% of patients experienced clinical benefit in the form of disease control, including tumor shrinkage in 21% of the patients. Two patients with late-line CCA, an aggressive tumor type and disease setting usually unresponsive to therapy, including IO therapies, achieved durable stable disease and one of the patients achieved durable tumor shrinkage. TPST-1120 and Nivolumab Combination Therapy Results: In the combination therapy portion of the trial, 15 evaluable patients with heavily-pretreated renal cell carcinoma, hepatocellular carcinoma and CCA were treated with oral twice-daily TPST-1120 and the anti-PD-1 therapy, nivolumab. All of the HCC and RCC patients had received an approved anti-PD-1 therapy in at least one prior line of therapy and discontinued that treatment due to disease progression. Promising objective responses were observed in two patients with late-line RCC who had previously progressed on anti-PD-1 therapy without an objective response. A third RECIST response was observed in a patient with late-line, heavily pre-treated CCA, a tumor type generally not responsive to anti-PD-1 alone. Notably, all three responders were treated at the two highest doses of TPST-1120. Safety: TPST-1120 was well tolerated as both a monotherapy and in combination with nivolumab. The majority of the treatment-related adverse events were Grade 1 and 2, and included nausea, fatigue and diarrhea. No dose-limiting toxicities were reported during dose escalation.

08:01 EDT MeaTech 3D granted patent for physical manipulation of cultured muscle tissue - MeaTech 3D has received its first patent out of several that are currently pending. The patent, granted by IP Australia, is based on the company's development of systems and methods to apply external forces to muscle tissue that result in the development of high-quality complex structured meat.

08:00 EDT Bombardier announces June 13 as effective date of share consolidation - Bombardier confirmed that the previously announced consolidation of the Corporation's issued and unissued Class A shares and Class B shares at a ratio of one post-consolidation share for every twenty-five pre-consolidation Class A shares or Class B shares is being implemented and will be effective on June 13, 2022. As such, the Corporation's Class A shares and Class B shares are expected to begin trading on the TSX, on a consolidated basis, on or about the Effective Date. As previously announced, the Class A shares and Class B shares will continue to be listed on the TSX under the symbols "BBD.A" and "BBD.B", respectively, although the post-consolidation Class A shares and Class B shares will be considered a substituted listing with new CUSIP and ISIN numbers. The Share Consolidation will reduce the number of issued and outstanding Class A shares and Class B shares of the Corporation from approximately 308,734,229 Class A shares and 2,134,347,470 Class B shares to approximately 12,349,369 Class A shares and 85,373,898 Class B shares.

07:54 EDT User reports indicate problems at Spotify, Downdetector says - Reference Link

07:52 EDT Immunocore appoints Siddharth Kaul to board of directors - Immunocore Holdings announces the appointment of Siddharth Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. He retired as Group Treasurer and Head of Business Planning and Analysis at Novartis in 2021 after a 17-year career at the company.

07:50 EDT Senti Bio debuts as publicly traded company on Nasdaq Global Market - Senti Biosciences announced the completion of its business combination with Dynamics Special Purpose Corp., a special purpose acquisition company. Senti Biosciences, Inc., the resulting combined company, will commence trading on the Nasdaq Global Market under the symbol "SNTI" on June 9, 2022. Senti Bio is developing next-generation cell and gene therapies engineered with gene circuits, which are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Senti Bio's oncology pipeline uses healthy adult donor-derived, natural killer cells engineered with chimeric antigen receptor gene circuits that are cryopreserved and dosed off-the-shelf. Senti Bio's oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma; and SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer cells while sparing healthy cells elsewhere in the body. In addition, the company is collaborating with Spark Therapeutics and BlueRock Therapeutics on applications of its gene circuit technology outside of oncology. Senti Bio received gross proceeds of approximately $140.3 million of the expected $156.5 million in connection with the business combination, which included funds held in DYNS's trust account of $84.5 million, $50.6 million of the expected $66.8 million in proceeds from a private investment in public equity financing that closed concurrently with the consummation of the business combination, and a recent $5.2 million investment by Leaps by Bayer, the impact investment arm of Bayer AG, through the purchase of a convertible note that was exchanged at the closing of the business combination for common equity with the same rights as the PIPE shares. Senti Bio expects the proceeds from this transaction, combined with cash on hand, to fund operations into 2024. Investors in DYNS include funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global, Invus, and funds and accounts advised by T. Rowe Price Associates, Inc., among others. Investors participating in the PIPE financing as of the closing of the business combination included 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global, Invus, NEA, Parker Institute for Cancer Immunotherapy, and T. Rowe Price funds, among others. Of the $66.8 million in subscriptions for the PIPE financing, $16.2 million has yet to be funded as one investor, who entered into a subscription agreement concurrently with Senti Bio and DYNS's execution of the business combination agreement in December 2021, has not funded its commitment. Senti Bio intends to enforce such one investor's legal obligations under its subscription agreement. Solely for purposes of consummating the business combination on June 8, 2022, Senti Bio agreed to waive the $150 million available cash closing condition under the business combination agreement previously entered into with DYNS. DYNS's board members, Dr. Omid Farokhzad and David Epstein, have joined the Senti Bio Board of Directors. The other Senti Bio board members are Susan Berland, Dr. James Collins, Dr. Brenda Cooperstone, Dr. Timothy Lu and Edward Mathers. Proceeds from the transaction are expected to provide Senti Bio with capital to further develop its gene circuit technologies and therapeutic pipeline, including: Conducting Investigational New Drug- enabling studies for SENTI-202 and SENTI-301; Building out clinical-scale current good manufacturing practice capabilities and enabling cGMP runs for off-the-shelf CAR-NK cell therapies; Alameda, CA, facility startup on track for year-end 2022; Filing IND applications for SENTI-202 and SENTI-301 in 2023; Advancing SENTI-202 and SENTI-301 toward Phase 1/2 dose escalation clinical trials; Advancing its gene circuit platform with additional programs, such as SENTI-401 towards an anticipated IND filing in 2024, for solid tumors; Building out its gene circuit platform to expand modalities and therapeutic areas through potential collaborations and/or partnerships.

07:47 EDT Teva to present latest data on AJOVY at 2022 AHS Annual Meeting - Teva Pharmaceuticals announced that eight abstracts examining real-world data to better understand the use of AJOVYinjection in patients with migraine will be presented at the 2022 American Headache Society, AHS, Annual Meeting held June 9-12, 2022, in Denver, Colorado. The data presented at this year's AHS meeting will focus on real-world use of AJOVY across different patient populations. Featured data will include a late-breaking poster presentation on real-world evidence in patients using concomitant gepants for acute migraine treatment, as well as results of a subgroup analysis from the Phase 3b FOCUS study examining the use of AJOVY in patients with difficult-to-treat migraine and comorbid obesity. In addition, a real-world effectiveness study of AJOVY in patients with refractory migraine who switched from erenumab will be highlighted at the meeting.

07:44 EDT Medicenna announces USPTO patent that 'strengthens IP protection' - Medicenna Therapeutics announced that the U.S. Patent and Trademark Office USPTO has issued U.S. Patent No. 11,352,402 titled, "Interleukin-4 Receptor-Binding Fusion Proteins And Uses Thereof." The patent provides intellectual property protection for composition and methods of treating degenerative diseases via administration of a fusion protein comprising an IL-4 or IL-13 Superkine and an anti-apoptotic Bcl-2 family polypeptide. The patent's term extends into at least 2038 without accounting for any potential extensions. "This latest patent strengthens our IP protection, diversifies our pipeline while underscoring the versatility of the Superkine platform," said Dr. Fahar Merchant, President and CEO of Medicenna. "By utilizing directed evolution, the Superkine platform creates highly selective tunable cytokines that can be seamlessly integrated with a variety of additional therapeutic moieties. Anti-apoptotic Bcl-2 proteins are essential to maintain the integrity of mitochondria, which are powerhouses of every cell. This has allowed us to generate novel biologics targeting a broad spectrum of conditions such as autoimmune disorders and neurodegenerative diseases. Looking forward, we believe our robust IP portfolio and preclinical data leave us well positioned to pursue partnerships aimed at facilitating the advancement of these discovery-stage assets and enable us to generate value across several therapeutic areas while remaining primarily focused on oncology and our lead MDNA11 program."

07:42 EDT KKR announces second reinsurance deal in Asia - Global Atlantic Financial Group, a majority-owned subsidiary of KKR, announced its second reinsurance transaction in Asia, signing an asset-intensive flow reinsurance transaction with a leading Singapore-based insurance company. This deal, executed through its Bermuda-based subsidiary Global Atlantic Assurance Limited, follows a $4.8bn block reinsurance transaction with AXA Hong Kong in July 2021. "Our client-centric and partnership-based approach has been well-received in the APAC region," said Manu Sareen, Co-President of Global Atlantic. "We are extremely proud of this new partnership and are seeing meaningful potential for future opportunities to deploy capital on endowment and asset-intensive life and annuity products in both flow and block transactions."

07:41 EDT Eagle Pharmaceuticals complete acquisition of Acacia Pharma - Eagle Pharmaceuticals announced it has completed the acquisition of the entire issued share capital of Acacia Pharma Group by way of a scheme of arrangement under Part 26 of the United Kingdom's Companies Act 2006. Key Highlights: Strong synergistic fit with Eagle's infrastructure and current and planned portfolio of hospital products; Two commercially compelling FDA-approved products: BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting despite prophylaxis. Eagle currently calls on healthcare providers and institutions representing over 70% of the expected BARHEMSYS addressable market opportunity; BARHEMSYS is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV. The total estimated annual U.S. addressable market for prophylaxis and rescue is $2.7 billion; BYFAVO is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less, with an estimated total addressable market in procedural sedation of more than $0.4 billion per year in the U.S. Opportunity to realize the full potential of BARHEMSYS and BYFAVO by leveraging Eagle's longstanding relationships and highly experienced, hospital-based salesforce; The addition of diversified but complementary revenue streams, accelerating Eagle's growth and strengthening its advantage in acute care; and Expected to be earnings accretive in 2024.

07:37 EDT Olema updates clinical progress in OP-1250 development program - Olema Pharmaceuticals announced clinical development progress for OP-1250, a complete estrogen receptor antagonis and a selective ER degrader n development for the treatment of metastatic breast cancer. "We are extremely pleased with the emerging clinical profile of OP-1250 and the encouraging progress achieved over the last six months. High investigator enthusiasm has led to rapid enrollment across the development program. In our Phase 1b monotherapy dose expansion, we have seen favorable tolerability and encouraging early anti-tumor activity. In the Phase 1b combination trial with palbociclib, two initial cohorts have completed the dose limiting toxicity evaluation period and we have demonstrated combinability for OP-1250 with no induced metabolism of palbociclib," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "We are entering an exciting period with the selection of our Recommended Phase 2 Dose later this month, followed by enrollment in our Phase 2 cohorts and plans to initiate an additional Phase 1b combination trial with each of ribociclib and alpelisib. We expect these datasets will further validate OP-1250's clinical profile and lay the foundation for our planned pivotal monotherapy study to begin next year." Olema continues to be well capitalized with sufficient cash to fund our planned research and development operations into the second half of 2024.

07:34 EDT Bluejay: FDA to consider plan to pursue a De Novo pathway for Symphony IL-6 test - Bluejay Diagnostics announced that the FDA has agreed to consider Bluejay's plan to pursue a De Novo submission for the Symphony IL-6 Test. In written feedback to the January 2022 submission of the FDA pre-submission briefing package, the FDA stated that Bluejay's Symphony IL-6 Test could be considered for the De Novo pathway. Neil Dey, Chief Executive Officer, said "We are excited for the opportunity to pursue the De Novo regulatory pathway. This confirms our belief that the Bluejay Symphony IL-6 Test has the potential to provide an innovative solution to the market. Bluejay continues to advance the Symphony IL-6 Test towards the Company's anticipated marketing application with the FDA, expected by year-end 2022."

07:32 EDT InMed Pharmaceuticals launches THCV, expanding portfolio of rare cannabinoids - InMed Pharmaceuticals is pleased to announce it has launched B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin into the health and wellness sector via its wholly-owned subsidiary, BayMedica. Although similar in name and structure to its intoxicating cousin THC, THCV has a slightly modified structure that leads to significantly different physiological effects, including being non-intoxicating. In addition, while THC is found abundantly in many strains of the Cannabis plant, THCV is a rare cannabinoid that is generally found in only trace amounts in the plant. D9-THCV has been researched for a variety of physiological benefits, most notably for its appetite suppressing effects, making it a compelling compound for use in weight management. It has also attracted interest for its potential ability to help maintain normal blood sugar levels and has been studied for a myriad of other effects. InMed is committed to developing products based on scientific evidence, and as previously announced, BayMedica has supplied d9-THCV to be evaluated in Radicle Science's "Radicle Energy" study on energy, focus/attention, appetite and weight/body mass index. The study is being conducted to provide valuable third party validation of the potential effects of d9-THCV.

07:21 EDT Idaho Strategic receives final approval for Diamon Creek REE drill program - Idaho Strategic Resources announced that it has received final approval for its Diamond Creek Rare Earth Element drill program scheduled to begin later this month. The Company's Diamond Creek Rare Earth Element property was initially discovered in the 1950's by the U.S. Government during extensive country-wide exploration efforts aimed at locating nuclear power related raw materials. This campaign resulted in the discovery of Thorium in areas of Lemhi County including substantial Rare Earth Element occurrences throughout Diamond Creek, Roberts, and Lemhi Pass. Idaho Strategics' 8-10-hole drill program is building on the base of knowledge and past surface exploration; including mapping, sampling, and handwritten notes, conducted by the United States Geological Survey, the Idaho Geological Survey, and the Department of Energy. The combination of having an extensive amount of successful prior surface exploration at Diamond Creek, coupled with the opportunity to advance the property through core drilling, is an exciting setup for Idaho Strategic. The samples from this drill program are to be used as part of IDR's participation in the Idaho Dept. of Commerce' IGEM program - a partnership between IDR, the U. of Idaho, Idaho National Labs, the Idaho Geological Survey, and the Center for Advanced Energy Studies. The IGEM program is focused on developing technologies for the environmentally responsible separation of Rare Earth Elements. In addition to Idaho Strategic receiving final approval for its drill program, it has also purchased a company office building in Salmon, Idaho. IDR prides itself on taking a community-based approach to mining and this is one of the first ways to differentiate the Company from some of the more 'temporary' groups within the industry.

07:18 EDT Alnylam Regeneron reports results from Phase 2 study of cemdisiran - Alnylam Pharmaceuticals (ALNY) announced today topline results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is in development in collaboration with Regeneron Pharmaceuticals (REGN) for the treatment of immunoglobulin A nephropathy. At Week 32, treatment with cemdisiran resulted in a 37 percent mean reduction from baseline in the 24-hour urine protein to creatinine ratio relative to placebo - the primary endpoint of the study. The results of secondary endpoints were also consistent with a therapeutic benefit of cemdisiran in IgAN. There were no significant drug-related safety signals. The primary endpoint of the study was the percent change in the 24-hour urine protein to creatinine ratio at Week 32. Secondary endpoints at Week 32 included: Percent of patients with partial clinical remission; Percent of patients with greater than 50% reduction in 24-hour proteinuria; Percent change from baseline in 24-hour proteinuria; Change from baseline in UPCR as measured in spot urine; Change from baseline in hematuria; and Frequency of adverse events. This Phase 2 study was descriptive only and did not include statistical hypothesis testing. Treatment with cemdisiran led to a 37% mean reduction in 24-hour urine protein to creatinine ratio relative to placebo. All secondary efficacy endpoints trended in favor of cemdisiran, supporting the therapeutic hypothesis. There were no serious or severe adverse events related to study drug, and the overall safety and tolerability profile of cemdisiran supports continued clinical development. One death was reported in the cemdisiran arm due to a post-surgical complication; this was not considered related to study drug by the investigator. There were no discontinuations from study drug due to AEs. Two of nine patients on placebo and 12 of 22 of patients on cemdisiran experienced treatment emergent AEs that were related to study drug.

07:17 EDT Evoqua Water opens new manufacturing facility in Singapore - Evoqua Water Technologies recently celebrated the opening of its new manufacturing facility based in Singapore, furthering the company's investment in Asia-Pacific, APAC, as demand continues to grow for innovative water treatment solutions in the region. The 19,000 square foot state-of-the-art facility will be the global manufacturing facility for Evoqua's Ionpure Continuous Electrodeionization, CEDI, products. The new facility supports efforts to localize production to better serve the increasing demand for ultrapure water solutions in the APAC region, predominately in the microelectronics and pharmaceutical industries. "The establishment of this new manufacturing facility supports Evoqua's growth and market development plans for the Asia-Pacific market," said Ron Keating, Evoqua's Chief Executive Officer. "Our expanded presence allows us to meet the growing needs of the APAC market, strengthening our commitment to helping our customers across the region address their critical water treatment needs."

07:11 EDT Freight Technologies integrates with newtrul - Freight Technologies completed its integration with newtrul, a centralized portal that connects shippers, brokers and over 100,000 carriers in the United States.

07:09 EDT BioCryst in pact with Pint to promote berotralstat in the pan-Latin America - BioCryst Pharmaceuticals announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO berotralstat in the pan-Latin America region. "We are pleased to join forces with Pint Pharma to bring our oral, once-daily therapy to hereditary angioedema patients in LATAM who are in need of a new treatment option. Pint Pharma is the ideal partner for BioCryst based on the team's deep experience in rare diseases that spans multiple aspects of commercialization and their established network across this important region," said Charlie Gayer, chief commercial officer of BioCryst. "Our partnership with BioCryst is significant for Pint Pharma given the critical unmet need among HAE patients in LATAM who are seeking an innovative treatment option for this serious disease. ORLADEYO has successfully launched in multiple markets across the globe, and we are privileged to leverage our expertise to support BioCryst in introducing this prophylactic therapy to the region," said David Munoz, chief executive officer and co-founder of Pint Pharma Under the terms of the agreement, Pint Pharma will be responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the pan-LATAM region. Pint Pharma is an Austria-based pharmaceutical company that has extensive experience developing, registering and commercializing rare disease and specialty treatments throughout Latin America and Europe.

07:07 EDT Can-Fite BioPharma announces publication of data for Piclidenoson, Namodenoson - Can-Fite BioPharma announced an article titled "Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data" was published in MDPI's open access scholarly journal Molecules. In the scientific community, A3AR is well established as a target for combatting inflammation and cancer. The target, Gi protein-coupled A3AR, is highly expressed in inflammatory and cancer cells, but not in normal cells. Data suggest Piclidenoson and Namodenoson could potentially be the first A3AR agonists to achieve FDA approval and provide clinicians with new oral and safe drugs in the arsenal for fighting psoriasis, liver cancer, and NASH. "As a leader in the development of A3AR targeting drugs, we are pleased to have this comprehensive article published in an open-source scientific journal. We believe providing data on our platform's mechanism of action and its performance in several clinical studies supports the advancement of knowledge and discovery specific to A3AR and increases its potential to become a widely used mechanism to treat chronic and acute disease," stated Can-Fite CEO Dr. Pnina Fishman.

07:05 EDT Tonix announces data on TNX-1500 organ transplant candidate at ATC - Tonix Pharmaceuticals Holding announced data from three oral presentations at the 2022 American Transplant Congress ATC by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital. The data involve studies of Tonix's TNX-1500 product candidate in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand , which is also known as CD154. Copies of the presentations are available under Scientific Presentations on the Tonix Pharmaceuticals corporate website at www.tonixpharma.com."There remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejections with acceptable level of tolerability. TNX-1500 is a third generation anti-CD40L mAb that has been designed by protein engineering to decrease Fc?RII binding and to reduce the potential for thrombosis. The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. We believe TNX-1500 has the potential for treating and preventing organ transplant rejection."

07:05 EDT Tiziana Life Sciences announces purchase of 18K common shares by chairman - Tiziana Life Sciences announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, purchased 18,000 common shares at $0.80 per share. The acquisition takes Mr Cerrone's interests from 37.58% to 37.60%.

07:04 EDT Fusion Pharmaceuticals provides update on solid tumor candidates pipeline - Fusion Pharmaceuticals announced updates on its Phase 1 clinical trial evaluating FPI-1434 as a monotherapy for the treatment of solid tumors expressing IGF-1R and its Phase 1 clinical trial evaluating FPI-1966 for the treatment of solid tumors expressing FGFR3. In the FPI-1434 trial, the company now expects to report Phase 1 safety, pharmacokinetics, and imaging data, including any evidence of anti-tumor activity, and details on the dosing regimen, in the first half of 2023, rather than in the second half of 2022. Fusion is also updating guidance for FPI-1966 and expects to dose the first patient in this study in the second half of 2022, rather than in 2Q22. Following the protocol amendment to incorporate the cold antibody study arm, sites have been slow to initiate and, as a result, patient enrollment in this portion of the study is now lagging prior forecasts. The company experienced similar study site startup challenges in the Phase 1 trial of FPI-1966. As a result, now expects the first patient to be dosed in the second half of this year. Delays are resulting from a combination of staffing/resourcing shortages and administrative complications with various review boards for radiopharmaceuticals at the trial sites.

07:04 EDT Lantronix to display OOBM solutions at Cisco Live - Lantronix announced that it will display its Out-of-Band Management solutions at Cisco Live, being held June 12-16, 2022, in Las Vegas. Lantronix, a Cisco Solutions Partner, will be at booth Number 3454. Lantronix OOBM solutions enable end-to-end business continuity across remote locations, data centers, branch offices and unmanned sites. At Cisco Live, Lantronix will showcase its ConsoleFlow cloud-based centralized device management platform with OOBM hardware, including the SLC 8000, the new EMG family of edge management gateways and the G520 series of next-generation IoT cellular gateways. Providing automated failover using Lantronix Connectivity Data Services, Lantronix's OOBM solutions are available with its LEVEL Technical Services to provide peace-of-mind service with a trusted account advisor who helps ensure maximum uptime for the data center and remote locations.

07:02 EDT Pennsylvania REIT highlights continued sales, traffic, leasing momentum - PREIT highlighted continued sales, traffic and leasing momentum across its portfolio. Traffic, sales and leasing activity at Cherry Hill Mall, Springfield Town Center and Woodland Mall demonstrate the strength of PREIT's portfolio despite continued inflationary pressure on consumers. Across these three properties, traffic through May was up nearly 10% over last year, rolling 12-month comparable sales grew by over 3% since the end of 2021 and leasing volume represents nearly 50% of portfolio new leasing activity year-to-date. These results are indicative of the momentum-building strategies, centered around a strong and relevant tenant mix, the PREIT team employs. At Cherry Hill Mall, PREIT's crown jewel where many new tenants enter the Philadelphia market, sales have improved to $944 per square foot, up from $936 as of December 31, 2021. To date, PREIT has executed new leases with nearly 45,000 square feet of tenants yet to open on the heels of the opening of new-to-portfolio additions, Warby Parker and Marc Cain, earlier this year. At Springfield Town Center, PREIT continues the transformation of the property into a vibrant multi-use hub and entertainment destination complete with amenities to complement top-notch restaurants, entertainment destinations that include the Regal Cinema, Dave & Buster's and the region's only Lego Discovery Center expected to open in 2023. Sales per square foot are up to $580 compared to just $558 at year end 2021. Leasing activity has been robust accounting for one third of the portfolio activity. Woodland Mall underwent a transformative redevelopment that was completed in 2019 and has experienced tremendous demand from consumers and tenants, with sales up 5.6% over year end to $667 per square foot. In 2021, the mall welcomed many new-to-portfolio tenants including Rose and Remington, Lovisa and Offline by aerie. This past April, Phoenix Theatres reinvented the moviegoing experience at the property.

06:59 EDT Aecom to provide environmental planning services for Toronto airports authority - Aecom has been selected by the Greater Toronto Airports Authority - GTAA - to develop a long-term environmental master plan for Toronto Pearson International Airport. The plan will focus on six key areas in support of GTAA's environmental policy - climate change, carbon neutrality and emissions, strategic energy use, water management, natural environment, and waste management. In this role, Aecom will suggest high level capital projects and operational changes to assist GTAA in meeting its environmental goals.

06:48 EDT Kennametal appoints Patrick Watson as CFO - Kennametal announced that Patrick Watson, currently Vice President Finance and Corporate Controller, will assume the role of Vice President and CDO effective immediately. Watson succeeds Damon Audia, who has served as CFO since September 2018 and is leaving the Company after a short transition period to pursue another opportunity. As CFO, Watson will serve as a member of the Company's Executive Leadership Team, reporting to President and CEO Christopher Rossi. He will play a critical role in advancing the Company's strategy and will be responsible for leading the Company's finance, investor relations, information technology and sourcing functions.

06:46 EDT BWX Technologies to build first advanced nuclear microreactor in U.S. - BWX Technologies will build the first advanced nuclear microreactor in the United States under a contract awarded by the U.S. Department of Defense Strategic Capabilities Office. The Project Pele full-scale transportable microreactor prototype will be completed and delivered in 2024 for testing at the Idaho National Laboratory. The prototype will be built under a cost-type contract valued at approximately $300M, depending on options selected, by BWXT Advanced Technologies LLC in facilities in Lynchburg, Virginia and Euclid, Ohio. Over the next two years, BWXT expects that approximately 120 employees will work on the project, including roughly 40 skilled trades, engineers and other positions that will be hired to support this effort and other projects.

06:35 EDT Planet 13 Holdings announces third Florida dispensary - Planet 13 Holdings announced the third location of its planned Florida dispensary network located in the city of Ocala. The location in Ocala is in a densly populated, busy retail corridor across the street from a Walmart Supercenter and an IMAX theater.

06:34 EDT Thomson Reuters announces voting results for election of directors - Thomson Reuters announced the voting results for the election of the company's Board of Directors at its annual meeting of shareholders held virtually yesterday. All 14 nominees were elected to the Thomson Reuters Board. Beth Wilson is a newly elected director and LaVerne Council stood for election by shareholders for the first time at the meeting. Each director elected will continue to hold office until Thomson Reuters next annual meeting of shareholders, or until the director resigns or a successor is elected or appointed. Thomson Reuters thanks Vance Opperman and Wulf von Schimmelmann, who decided not to stand for re-election at the meeting. Mike Daniels was appointed by the Board as the new Lead Independent Director in connection with Vance's retirement as a director. For the other items of business at the annual meeting, shareholders re-appointed PricewaterhouseCoopers LLP as the company's auditor and approved an advisory resolution on executive compensation. A final report on voting results has been filed with the Canadian securities regulatory authorities and furnished to the U.S. Securities and Exchange Commission.

06:32 EDT BitNile investing $12M in Ecoark Holdings - BitNile (NILE) announced a strategic partnership and investment into Ecoark Holdings (ZEST). BitNile's subsidiary, Digital Power Lending, has agreed to purchase $12M of a new series of convertible preferred stock of Ecoark, which will be paid no later than June 29. Ecoark intends to deploy significant proceeds via its subsidiary White River towards an oil drilling program across its cumulative 30,000 acres of active mineral leases at both shallow, intermediate, and deep levels. Ecoark will also deploy additional proceeds via its subsidiary Agora Digital to provide BitNile with up to 78 MW of power within the State of Texas for digital asset mining capacity, subject to BitNile proceeding with this facility after having conducted the requisite due diligence. The Agora Digital power capacity would expedite BitNile's recently announced plans to significantly expand its Bitcoin mining production capacity, including growing its number of deployed Bitcoin miners to 20,600, an expected mining production capacity of 2.24 exahashes per second.

06:31 EDT Target raises quarterly dividend 20% to $1.08 per share - The board of directors of Target Corporation has declared a quarterly dividend of $1.08 per common share, a 20% increase from the prior quarterly dividend of 90c. The dividend is payable Sept. 10, 2022 to shareholders of record at the close of business August 17, 2022.

06:16 EDT William Penn Bancorp announces stock repurchase program up to 5% of shares - William Penn Bancorporation announced that the Company's Board of Directors has authorized a new stock repurchase program to acquire up to 771,445 shares, or approximately 5.0%, of the Company's currently issued and outstanding common stock, commencing upon the completion of the Company's existing stock repurchase program. The new stock repurchase program was adopted following the Company's consultation with the Federal Reserve Bank of Philadelphia. On March 11, 2022, the Company announced its first stock repurchase program, which became effective on March 25, 2022 and authorized the purchase of up to 758,528 shares. Under this previously announced program, 234,618 shares of common stock have been repurchased at a cost of $2,859,013, or $12.19 per share. As of June 8, 2022, there are 523,910 shares remaining to be repurchased under this existing program.

06:13 EDT B2Gold's proposals to shareholders recommended by ISS, Glass Lewis - B2Gold announced the support of Institutional Shareholder Services - ISS - and Glass Lewis, who have both recommended that shareholders vote for the Say on Pay resolution as well as vote for all other proposed items to be considered at the upcoming Annual General & Special Meeting of Shareholders of B2Gold. ISS and Glass Lewis are third party proxy advisory firms who provide independent analysis and proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.

06:12 EDT Tuniu expects cash to meet requirements for next twelve months - As of March 31, 2022, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB929.5 million. The COVID-19 pandemic has negatively impacted our business operations, and will continue to impact our results of operations and cash flows for subsequent periods. Based on our liquidity assessment and management actions, we believe that our available cash, cash equivalents and maturity of investments will be sufficient to meet our working capital requirements and capital expenditures in the ordinary course of business for the next twelve months.

06:10 EDT Daqo New Energy unit receives CSRC approval for private offering - Daqo New Energy announced that its subsidiary, Xinjiang Daqo New Energy, has received approval from the China Securities Regulatory Commission for its planned private offering in China's A-share market. Xinjiang Daqo intends to raise up to RMB11B from this private offering, including approximately RMB8B of the gross proceeds to be used for its 100,000 metric tons of polysilicon expansion project in Baotou City, Inner Mongolia, China, and the rest of the proceeds for its working capital purposes. This transaction is subject to market conditions. The approval from the China Securities Regulatory Commission is valid until May 29, 2023.

06:08 EDT BKV, EnLink Midstream partner on carbon sequestration project - BKV Corporation and EnLink Midstream announced that they have reached a Phase I Final Investment Decision and entered into a definitive agreement to develop a carbon capture and sequestration project in the Barnett Shale region of North Texas. Carbon sequestration is the process of capturing and permanently storing carbon dioxide, which reduces the amount of pollutive carbon dioxide in the atmosphere. Under their agreement, BKV will continue to produce natural gas containing carbon dioxide from its Barnett Shale area operations, and EnLink will transport this natural gas via its modified pipeline and facility infrastructure to the EnLink natural gas processing plant in Bridgeport, Texas. At the Bridgeport plant, the carbon dioxide waste stream will be captured, compressed

06:05 EDT Sanuk, Grateful Dead announce sixth iteration of ongoing collaboration - Sanuk announced the sixth iteration of its ongoing collaboration with iconic rock band the Grateful Dead, powered by Warner Music Artist Services. The capsule collection features a premium lineup of men's and women's summer styles made with natural, repurposed and recycled materials and honors the Grateful Dead's legacy with iconic band logos. This fresh Sanuk x Grateful Dead collection introduces four new styles and colorways to the collaboration roster, featuring new earth tones, floral boho patterns and funky geometric pops of color. Special Dead details in the collaboration include debossed band emblems, band tags, premium printed footbeds and stamped hemp-lined uppers.The sixth installment of the SANUK & GRATEFUL DEAD collection launches today exclusively on Sanuk.com. Retail prices range from $50-70.

06:02 EDT NextMart's Emco launches acquisition program of New Mexico water rights - NextMart announced that its wholly-owned subsidiary, Emco Oilfield Services, has launched an acquisition program of New Mexico water rights to expand its water capacity for own water stations in the Permian Basin. The Permian Basin is the largest oilfield in the world. EMCO is currently servicing over sixty clients including major oil companies such as Exxon Mobile's subsidiary, XTO, Chevron, Conoco Phillips, Occidental, and major independent public oil companies such as EOG, Devon, Cimarex, Noble Energy and many more. The acquisition of more New Mexico water rights is in direct response to the current fast-growing needs of its current clients, and new clients that are coming on board, due to the increased oil and gas activity in the Permian Basin. Emco will continue to transport water to and from oil and gas well drill sites in the Permian Basin, which has generated an estimated $40 million in revenues for Emco since 2018. Going forward, with its own water stations, Emco can generate an additional revenue stream that can be significant for its aggressive growth plans. Approximately half the drilling rigs in the U.S. are stationed in the Permian Basin drilling thousands of oil and gas wells annually to provide for the U.S. energy needs.

05:57 EDT Best Inc. regains NYSE compliance - Best Inc. announced that it has received a letter from the New York Stock Exchange, dated June 2, notifying the company that it has regained compliance with the NYSE's continued listing standards.

05:54 EDT Infosys, TK Elevator announce strategic collaboration - Infosys announced a global strategic collaboration with TK Elevator, based out of Dusseldorf, Germany. The global seven-year collaboration is an extension of the successful modernization of TK Elevator's IT infrastructure in Europe and Africa. As part of this engagement, Infosys will consolidate and harmonize the global service desk and workplace operations. Infosys will provide AI-powered IT helpdesk services, digital workplace management, as well as network services, powered by Infosys Cobalt-driven automation framework. This will humanize TK Elevator's workplace experience by building a resilient enterprise and digitally transforming their underlying IT infrastructure. Infosys will aim to boost cybersecurity and enhance digital experience for TK Elevator's end users, by leveraging its deep domain expertise, industry-grade IT infrastructure modernization capabilities, and a strong global presence. The collaboration, while improving availability of IT infrastructure, will reduce overall IT operational costs.

05:50 EDT Sinovac Biotech receives WHO prequalification for its Poliomyelitis Vaccine - Sinovac Biotech announced that it received the World Health Organization prequalification for its Poliomyelitis Vaccine on June 2. The vaccine will be available for United Nations agencies to purchase to support the global polio endgame strategy. Sinovac's sIPV is applicable for active immunization against polioviruses Type 1, 2, and 3 for children and infants aged two months and above. The basic immunization schedule is three doses with the first dose for infants at 2 months old, followed by two successive doses 4-6 weeks apart. One dose should be injected as a booster at the age of 18 months. Other age groups can also receive the vaccine if needed. The vaccine can be used sequentially with oral polio attenuated live vaccine.